Glucocorticoid	B-protein
receptors	I-protein
and	O
steroid	O
sensitivity	O
in	O
normal	O
and	O
neoplastic	O
human	O
lymphoid	O
tissues	O
:	O
a	O
review	O
.	O

The	O
determination	O
of	O
estrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
in	O
breast	O
cancer	O
has	O
been	O
shown	O
to	O
be	O
useful	O
in	O
predicting	O
the	O
response	O
to	O
endocrine	O
therapy	O
.	O

Given	O
their	O
well-known	O
inhibitory	O
effects	O
on	O
lymphoid	O
tissue	O
,	O
glucocorticoids	O
have	O
been	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O

Given	O
these	O
facts	O
,	O
over	O
the	O
last	O
10	O
years	O
,	O
several	O
investigators	O
have	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
to	O
see	O
whether	O
their	O
number	O
correlated	O
with	O
glucocorticoid	O
responsiveness	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O

No	O
clear	O
correlation	O
could	O
be	O
established	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
in	O
vitro	O
action	O
of	O
steroids	O
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
.	O

In	O
contrast	O
,	O
attempts	O
to	O
correlate	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphocytic	O
leukemia	O
to	O
in	O
vivo	O
steroid	O
responsiveness	O
and	O
immunological	O
type	O
using	O
the	O
whole-cell-binding	O
assay	O
for	O
receptor	O
determination	O
and	O
selecting	O
the	O
patients	O
according	O
to	O
age	O
and	O
immunological	O
criteria	O
have	O
been	O
more	O
successful	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
44	NULL
,	NULL
431-437	NULL
,	NULL
February	NULL
1984	NULL
]	NULL
Glucocorticoid	NULL
Receptors	NULL
and	NULL
Steroid	NULL
Sensitivity	NULL
in	NULL
Normal	NULL
and	NULL
Neoplastic	NULL
Human	NULL
Lymphoid	NULL
Tissues	NULL
:	NULL
A	NULL
Review	NULL
'	NULL
Frangoise	NULL
Homo-Delarche	NULL
INSERM	NULL
U7	NULL
,	NULL
Physiology	NULL
and	NULL
Pharmacology	NULL
,	NULL
Hopital	NULL
Necker	NULL
,	NULL
161	NULL
rue	NULL
de	NULL
Sevres	NULL
,	NULL
75015	NULL
Paris	NULL
,	NULL
France	NULL
Abstract	NULL
The	NULL
determination	NULL
of	NULL
estrogen	NULL
and	NULL
progesterone	NULL
receptors	NULL
in	NULL
breast	NULL
cancer	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
useful	NULL
in	NULL
predicting	NULL
the	NULL
response	NULL
to	NULL
endocrine	NULL
therapy	NULL
.	NULL

Given	NULL
their	NULL
well-known	NULL
inhibitory	NULL
effects	NULL
on	NULL
lymphoid	NULL
tissue	NULL
,	NULL
glucocorticoids	NULL
have	NULL
been	NULL
used	NULL
widely	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
leukemia	NULL
.	NULL

Given	NULL
these	NULL
facts	NULL
,	NULL
over	NULL
the	NULL
last	NULL
10	NULL
years	NULL
,	NULL
several	NULL
investigators	NULL
have	NULL
measured	NULL
the	NULL
number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
lymphoid	NULL
tissue	NULL
to	NULL
see	NULL
whether	NULL
their	NULL
number	NULL
correlated	NULL
with	NULL
glucocorticoid	NULL
responsiveness	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
.	NULL

No	NULL
clear	NULL
correlation	NULL
could	NULL
be	NULL
established	NULL
between	NULL
the	NULL
level	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
action	NULL
of	NULL
steroids	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
lymphoid	NULL
tissue	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
attempts	NULL
to	NULL
correlate	NULL
glucocorticoid	NULL
receptor	NULL
levels	NULL
in	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
to	NULL
in	NULL
vivo	NULL
steroid	NULL
responsiveness	NULL
and	NULL
immunological	NULL
type	NULL
using	NULL
the	NULL
whole-cell-binding	NULL
assay	NULL
for	NULL
receptor	NULL
determination	NULL
and	NULL
selecting	NULL
the	NULL
patients	NULL
according	NULL
to	NULL
age	NULL
and	NULL
immunological	NULL
criteria	NULL
have	NULL
been	NULL
more	NULL
successful	NULL
.	NULL

Introduction	NULL
It	NULL
has	NULL
been	NULL
known	NULL
for	NULL
a	NULL
long	NULL
time	NULL
that	NULL
glucocorticoids	NULL
exert	NULL
many	NULL
physiological	NULL
and	NULL
pharmacological	NULL
effects	NULL
on	NULL
mammalian	NULL
lymphoid	NULL
tissues	NULL
.	NULL

in	NULL
vivo	NULL
administration	NULL
of	NULL
corticosteroids	NULL
or	NULL
adrenalectomy	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
marked	NULL
changes	NULL
in	NULL
the	NULL
size	NULL
of	NULL
lymphoid	NULL
organs	NULL
as	NULL
well	NULL
as	NULL
in	NULL
lymphocyte	NULL
circulation	NULL
and	NULL
to	NULL
alter	NULL
many	NULL
immunological	NULL
reactions	NULL
(	NULL
11	NULL
)	NULL
.	NULL

in	NULL
vitro	NULL
,	NULL
glucocorticoids	NULL
are	NULL
generally	NULL
considered	NULL
as	NULL
catabolic	NULL
agents	NULL
that	NULL
induce	NULL
an	NULL
inhibition	NULL
of	NULL
membrane	NULL
transport	NULL
and	NULL
macromolecular	NULL
synthesis	NULL
leading	NULL
to	NULL
an	NULL
arrest	NULL
of	NULL
cell	NULL
growth	NULL
,	NULL
sometimes	NULL
accompanied	NULL
by	NULL
cell	NULL
lysis	NULL
(	NULL
54	NULL
)	NULL
.	NULL

These	NULL
compounds	NULL
are	NULL
also	NULL
able	NULL
to	NULL
modify	NULL
several	NULL
immunological	NULL
functions	NULL
in	NULL
vitro	NULL
(	NULL
1	NULL
)	NULL
.	NULL

These	NULL
widespread	NULL
effects	NULL
on	NULL
lymphoid	NULL
cell	NULL
metabolism	NULL
and	NULL
function	NULL
constitute	NULL
the	NULL
basis	NULL
for	NULL
the	NULL
use	NULL
of	NULL
glucocorticoid	NULL
hormones	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
immunological	NULL
and	NULL
inflammatory	NULL
diseases	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
lymphoid	NULL
cell	NULL
neoplasias	NULL
.	NULL

According	NULL
to	NULL
the	NULL
classical	NULL
mechanism	NULL
of	NULL
steroid	NULL
hormone	NULL
action	NULL
,	NULL
which	NULL
includes	NULL
a	NULL
preliminary	NULL
step	NULL
of	NULL
interaction	NULL
of	NULL
the	NULL
steroid	NULL
with	NULL
cytoplasmic	NULL
receptors	NULL
(	NULL
53	NULL
)	NULL
,	NULL
numerous	NULL
studies	NULL
have	NULL
been	NULL
devoted	NULL
to	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
or	NULL
not	NULL
the	NULL
receptor	NULL
content	NULL
of	NULL
lymphoid	NULL
cells	NULL
may	NULL
be	NULL
representative	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
sensitivity	NULL
.	NULL

The	NULL
different	NULL
methods	NULL
used	NULL
to	NULL
measure	NULL
steroid	NULL
receptor	NULL
levels	NULL
as	NULL
well	NULL
as	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
sensitivity	NULL
are	NULL
listed	NULL
in	NULL
Table	NULL
1.	NULL
!	NULL

Part	NULL
of	NULL
this	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
76-7-1669	NULL
from	NULL
DGRST	NULL
,	NULL
by	NULL
Grant	NULL
58-78-90	NULL
from	NULL
INSERM	NULL
,	NULL
and	NULL
by	NULL
the	NULL
National	NULL
Cancer	NULL
Institute-INSERM	NULL
Collaborative	NULL
Agreement	NULL
on	NULL
Hormonal	NULL
Regulation	NULL
and	NULL
Cancer	NULL
(	NULL
1976/1977	NULL
)	NULL
.	NULL

Received	NULL
May	NULL
5	NULL
,	NULL
1983	NULL
;	NULL
accepted	NULL
October	NULL
6	NULL
,	NULL
1983	NULL
.	NULL

FEBRUARY	NULL
1984	NULL
This	NULL
paper	NULL
presents	NULL
a	NULL
critical	NULL
review	NULL
of	NULL
GR	NULL
determination	NULL
as	NULL
an	NULL
index	NULL
of	NULL
steroid	NULL
sensitivity	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
human	NULL
lymphoid	NULL
tissue	NULL
.	NULL

Normal	NULL
human	NULL
lymphoid	NULL
cells	NULL
Aithough	NULL
many	NULL
studies	NULL
have	NULL
attempted	NULL
to	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
leukemic	NULL
lymphoid	NULL
tissues	NULL
,	NULL
only	NULL
a	NULL
few	NULL
have	NULL
actually	NULL
related	NULL
the	NULL
extent	NULL
of	NULL
steroid	NULL
action	NULL
in	NULL
normal	NULL
human	NULL
lymphoid	NULL
cells	NULL
to	NULL
the	NULL
level	NULL
of	NULL
GR	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
,	NULL
the	NULL
number	NULL
of	NULL
GR	NULL
was	NULL
determined	NULL
by	NULL
whole-cell	NULL
assay	NULL
in	NULL
children	NULL
's	NULL
thymocytes	NULL
and	NULL
bone	NULL
marrow	NULL
as	NULL
well	NULL
as	NULL
in	NULL
adult	NULL
blood	NULL
and	NULL
lymph	NULL
node	NULL
lymphocytes	NULL
in	NULL
a	NULL
number	NULL
of	NULL
studies	NULL
(	NULL
5	NULL
,	NULL
13	NULL
,	NULL
31	NULL
,	NULL
32	NULL
,	NULL
36	NULL
,	NULL
43	NULL
,	NULL
46	NULL
,	NULL
56	NULL
,	NULL
58	NULL
,	NULL
63	NULL
,	NULL
70	NULL
)	NULL
.	NULL

It	NULL
is	NULL
apparent	NULL
that	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
found	NULL
in	NULL
blood	NULL
lymphocytes	NULL
is	NULL
very	NULL
similar	NULL
in	NULL
the	NULL
various	NULL
reports	NULL
and	NULL
ranged	NULL
from	NULL
3	NULL
to	NULL
7000	NULL
sites	NULL
per	NULL
cell	NULL
with	NULL
a	NULL
K	NULL
,	NULL
of	NULL
around	NULL
107°	NULL
m.	NULL
No	NULL
significant	NULL
difference	NULL
could	NULL
be	NULL
seen	NULL
between	NULL
normal	NULL
T-	NULL
and	NULL
B-cells	NULL
,	NULL
but	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
T-cells	NULL
are	NULL
heterogeneous	NULL
with	NULL
respect	NULL
to	NULL
their	NULL
quantity	NULL
of	NULL
GR	NULL
(	NULL
17	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
number	NULL
of	NULL
receptors	NULL
measured	NULL
in	NULL
either	NULL
human	NULL
thymus	NULL
cells	NULL
or	NULL
lymph	NULL
node	NULL
lymphocytes	NULL
was	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
blood	NULL
lymphocytes	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
GR	NULL
levels	NULL
in	NULL
normal	NULL
bone	NULL
marrow	NULL
were	NULL
3	NULL
to	NULL
5	NULL
times	NULL
higher	NULL
than	NULL
in	NULL
other	NULL
lymphoid	NULL
tissues	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Monocyte	NULL
depletion	NULL
prior	NULL
to	NULL
the	NULL
determination	NULL
of	NULL
blood	NULL
lymphocyte	NULL
receptors	NULL
appeared	NULL
to	NULL
be	NULL
necessary	NULL
,	NULL
since	NULL
monocytes	NULL
contain	NULL
approximately	NULL
2	NULL
times	NULL
more	NULL
receptors	NULL
than	NULL
lymphocytes	NULL
(	NULL
17	NULL
,	NULL
46	NULL
)	NULL
.	NULL

if	NULL
we	NULL
consider	NULL
the	NULL
effect	NULL
of	NULL
steroids	NULL
on	NULL
cell	NULL
viability	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
human	NULL
lymphoid	NULL
cells	NULL
are	NULL
extremely	NULL
resistant	NULL
to	NULL
them	NULL
when	NULL
compared	NULL
to	NULL
rodent	NULL
lymphoid	NULL
cells	NULL
.	NULL

Mouse	NULL
thymocytes	NULL
undergo	NULL
a	NULL
50	NULL
%	NULL
cell	NULL
lysis	NULL
after	NULL
6	NULL
hr	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
m	NULL
dexamethasone	NULL
(	NULL
12	NULL
,	NULL
34	NULL
)	NULL
,	NULL
whereas	NULL
human	NULL
lymphocytes	NULL
are	NULL
not	NULL
killed	NULL
even	NULL
during	NULL
longer	NULL
incubation	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
(	NULL
5	NULL
,	NULL
26	NULL
,	NULL
65	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
another	NULL
method	NULL
to	NULL
determine	NULL
steroid	NULL
action	NULL
in	NULL
vitro	NULL
,	NULL
ie	NULL
.	NULL

,	NULL
its	NULL
effect	NULL
on	NULL
nucleoside	NULL
incorporation	NULL
into	NULL
RNA	NULL
and	NULL
DNA	NULL
,	NULL
is	NULL
used	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
the	NULL
glucocorticoid	NULL
effect	NULL
can	NULL
be	NULL
very	NULL
different	NULL
from	NULL
one	NULL
cell	NULL
population	NULL
to	NULL
another	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Human	NULL
thymocytes	NULL
appeared	NULL
to	NULL
be	NULL
extremely	NULL
sensitive	NULL
to	NULL
the	NULL
inhibitory	NULL
action	NULL
of	NULL
steroids	NULL
(	NULL
32	NULL
)	NULL
,	NULL
whereas	NULL
peripheral	NULL
and	NULL
lymph	NULL
node	NULL
lymphocytes	NULL
were	NULL
less	NULL
affected	NULL
(	NULL
5	NULL
,	NULL
36	NULL
)	NULL
.	NULL

These	NULL
differences	NULL
observed	NULL
between	NULL
thymocytes	NULL
and	NULL
peripheral	NULL
lymphocytes	NULL
are	NULL
probably	NULL
related	NULL
to	NULL
the	NULL
stage	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

Claman	NULL
(	NULL
11	NULL
)	NULL
postulated	NULL
that	NULL
the	NULL
in	NULL
vivo	NULL
shrinkage	NULL
of	NULL
the	NULL
infant	NULL
thymus	NULL
after	NULL
hydrocortisone	NULL
administration	NULL
could	NULL
be	NULL
explained	NULL
in	NULL
terms	NULL
of	NULL
growth	NULL
inhibition	NULL
.	NULL

Since	NULL
the	NULL
rate	NULL
of	NULL
cell	NULL
division	NULL
in	NULL
infants	NULL
is	NULL
very	NULL
high	NULL
,	NULL
any	NULL
agent	NULL
which	NULL
blocks	NULL
cell	NULL
proliferation	NULL
without	NULL
changing	NULL
intrathymic	NULL
cell	NULL
death	NULL
would	NULL
cause	NULL
a	NULL
decrease	NULL
in	NULL
thymus	NULL
size	NULL
(	NULL
10-12	NULL
)	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
GR	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
;	NULL
ALL	NULL
,	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
;	NULL
CLL	NULL
,	NULL
chronic	NULL
tymphocytic	NULL
leukemia	NULL
;	NULL
PBL	NULL
,	NULL
pedpheralbloodlympm-cyte	NULL
.	NULL

431	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

F.	NULL
Homo-Delarche	NULL
Table	NULL
1	NULL
Different	NULL
experimental	NULL
procedures	NULL
for	NULL
the	NULL
determination	NULL
of	NULL
glucocorticoid	NULL
sensitivity	NULL
Receptor	NULL
content	NULL
Total	NULL
binding	NULL
(	NULL
cytoplasmic	NULL
+	NULL
nuclear	NULL
)	NULL
Nuclear	NULL
bindi	NULL
Steroid	NULL
effect	NULL
on	NULL
glucose	NULL
and	NULL
amino	NULL
acid	NULL
transport	NULL
Steroid	NULL
effect	NULL
on	NULL
precursor	NULL
incorporation	NULL
into	NULL
proteins	NULL
,	NULL
RNA	NULL
,	NULL
and	NULL
DNA	NULL
Short-term	NULL
response	NULL
to	NULL
glucocorticoids	NULL
alone	NULL
(	NULL
variation	NULL
in	NULL
blast	NULL
cell	NULL
count	NULL
)	NULL
Response	NULL
to	NULL
combined	NULL
chemotherapy	NULL
Achievement	NULL
of	NULL
complete	NULL
remission	NULL
Duration	NULL
of	NULL
complete	NULL
remission	NULL
Survival	NULL
In	NULL
vitro	NULL
sensitivity	NULL
In	NULL
vivo	NULL
sensitivity	NULL
With	NULL
regard	NULL
to	NULL
the	NULL
in	NULL
vivo	NULL
action	NULL
of	NULL
glucocorticoids	NULL
in	NULL
normal	NULL
humans	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
steroids	NULL
induce	NULL
in	NULL
vivo	NULL
a	NULL
transient	NULL
lymphopenia	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Although	NULL
both	NULL
T-	NULL
and	NULL
B-lymphocytes	NULL
are	NULL
removed	NULL
from	NULL
the	NULL
circulation	NULL
and	NULL
sequestered	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
there	NULL
is	NULL
a	NULL
proportionally	NULL
greater	NULL
depletion	NULL
of	NULL
circulatory	NULL
T-lymphocytes	NULL
,	NULL
more	NULL
precisely	NULL
of	NULL
a	NULL
functionally	NULL
defined	NULL
T-cell	NULL
subpopulation	NULL
(	NULL
19	NULL
,	NULL
21	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
selective	NULL
lymphodepletive	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
could	NULL
not	NULL
be	NULL
explained	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
detectable	NULL
differences	NULL
in	NULL
GR	NULL
levels	NULL
in	NULL
the	NULL
different	NULL
T-cell	NULL
subpopulations	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Neoplastic	NULL
human	NULL
lymphoid	NULL
tissue	NULL
Glucocorticoids	NULL
have	NULL
been	NULL
used	NULL
for	NULL
more	NULL
than	NULL
20	NULL
years	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
leukemia	NULL
,	NULL
first	NULL
alone	NULL
and	NULL
now	NULL
as	NULL
a	NULL
part	NULL
of	NULL
combined	NULL
chemotherapy	NULL
(	NULL
4	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
,	NULL
however	NULL
,	NULL
that	NULL
some	NULL
patients	NULL
either	NULL
are	NULL
resistant	NULL
to	NULL
them	NULL
at	NULL
the	NULL
outset	NULL
or	NULL
cease	NULL
to	NULL
be	NULL
responsive	NULL
during	NULL
the	NULL
course	NULL
of	NULL
the	NULL
treatment	NULL
.	NULL

Since	NULL
determination	NULL
of	NULL
estrogen	NULL
and	NULL
progesterone	NULL
receptors	NULL
in	NULL
breast	NULL
cancer	NULL
represents	NULL
an	NULL
important	NULL
element	NULL
in	NULL
the	NULL
therapeutic	NULL
management	NULL
of	NULL
the	NULL
disease	NULL
(	NULL
52	NULL
)	NULL
,	NULL
similar	NULL
studies	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
cases	NULL
of	NULL
leukemia	NULL
,	NULL
in	NULL
order	NULL
to	NULL
select	NULL
in	NULL
advance	NULL
the	NULL
patients	NULL
who	NULL
are	NULL
likely	NULL
to	NULL
respond	NULL
to	NULL
steroid	NULL
therapy	NULL
.	NULL

Acute	NULL
Lymphocytic	NULL
Leukemia	NULL
Ten	NULL
years	NULL
ago	NULL
,	NULL
Lippman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
47	NULL
)	NULL
first	NULL
presented	NULL
promising	NULL
results	NULL
.	NULL

They	NULL
showed	NULL
,	NULL
using	NULL
a	NULL
cytosolic	NULL
assay	NULL
,	NULL
that	NULL
the	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
previously	NULL
untreated	NULL
ALL	NULL
contained	NULL
high	NULL
levels	NULL
of	NULL
receptors	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
also	NULL
sensitive	NULL
to	NULL
steroid	NULL
action	NULL
in	NULL
vitro	NULL
as	NULL
well	NULL
as	NULL
in	NULL
vivo	NULL
.	NULL

They	NULL
showed	NULL
also	NULL
that	NULL
patients	NULL
previously	NULL
treated	NULL
with	NULL
corticosteroids	NULL
who	NULL
failed	NULL
to	NULL
respond	NULL
to	NULL
additional	NULL
treatment	NULL
had	NULL
barely	NULL
detectable	NULL
levels	NULL
of	NULL
receptors	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
cells	NULL
of	NULL
these	NULL
patients	NULL
were	NULL
insensitive	NULL
to	NULL
steroids	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
potential	NULL
clinical	NULL
implication	NULL
of	NULL
this	NULL
correlation	NULL
between	NULL
receptor	NULL
content	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
chemotherapy	NULL
has	NULL
prompted	NULL
several	NULL
groups	NULL
to	NULL
undertake	NULL
comparable	NULL
studies	NULL
.	NULL

It	NULL
soon	NULL
appeared	NULL
that	NULL
,	NULL
when	NULL
assayed	NULL
by	NULL
the	NULL
whole-cell	NULL
method	NULL
,	NULL
all	NULL
peripheral	NULL
leukocytes	NULL
isolated	NULL
from	NULL
patients	NULL
with	NULL
ALL	NULL
contain	NULL
specific	NULL
receptors	NULL
for	NULL
glucocorticoids	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
.	NULL

The	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
ranged	NULL
from	NULL
1,000	NULL
to	NULL
more	NULL
than	NULL
20,000	NULL
(	NULL
8	NULL
,	NULL
15	NULL
,	NULL
30	NULL
,	NULL
33	NULL
,	NULL
37	NULL
,	NULL
42	NULL
,	NULL
49	NULL
,	NULL
56	NULL
,	NULL
57	NULL
)	NULL
.3	NULL
The	NULL
affinities	NULL
of	NULL
these	NULL
°F	NULL
,	NULL
.	NULL

F.	NULL
Quddus	NULL
,	NULL
S.	NULL
H.	NULL
Kauffmann	NULL
,	NULL
M.	NULL
Roper	NULL
,	NULL
B.	NULL
Dowell	NULL
,	NULL
J.	NULL
Pullen	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Leventhal	NULL
.	NULL

Glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
level	NULL
in	NULL
pediatric	NULL
leukemia	NULL
cells	NULL
,	NULL
personal	NULL
432	NULL
receptors	NULL
for	NULL
the	NULL
steroid	NULL
were	NULL
comparable	NULL
to	NULL
those	NULL
determined	NULL
in	NULL
normal	NULL
humans	NULL
.	NULL

It	NULL
was	NULL
recently	NULL
demonstrated	NULL
that	NULL
the	NULL
use	NULL
of	NULL
a	NULL
cytosolic	NULL
assay	NULL
instead	NULL
of	NULL
the	NULL
whole-cell	NULL
assay	NULL
leads	NULL
to	NULL
a	NULL
marked	NULL
underestimation	NULL
of	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
(	NULL
up	NULL
to	NULL
80	NULL
%	NULL
)	NULL
(	NULL
38	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Several	NULL
reasons	NULL
may	NULL
account	NULL
for	NULL
this	NULL
difference	NULL
,	NULL
mainly	NULL
the	NULL
failure	NULL
to	NULL
measure	NULL
the	NULL
receptor	NULL
in	NULL
the	NULL
nuclear	NULL
com-partment	NULL
,	NULL
but	NULL
also	NULL
the	NULL
release	NULL
of	NULL
proteolytic	NULL
enzymes	NULL
that	NULL
partially	NULL
inactivate	NULL
the	NULL
receptor	NULL
during	NULL
cytosol	NULL
preparation	NULL
or	NULL
even	NULL
the	NULL
failure	NULL
to	NULL
break	NULL
some	NULL
cells	NULL
during	NULL
homogenization	NULL
.	NULL

It	NULL
is	NULL
now	NULL
widely	NULL
recognized	NULL
that	NULL
ALL	NULL
is	NULL
a	NULL
strongly	NULL
heterogeneous	NULL
disease	NULL
with	NULL
regard	NULL
to	NULL
its	NULL
clinical	NULL
and	NULL
immunological	NULL
aspects	NULL
.	NULL

Several	NULL
groups	NULL
have	NULL
thus	NULL
attempted	NULL
to	NULL
establish	NULL
a	NULL
relationship	NULL
between	NULL
the	NULL
number	NULL
of	NULL
receptors	NULL
and	NULL
the	NULL
immunological	NULL
markers	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
in	NULL
the	NULL
childhood	NULL
form	NULL
,	NULL
``	NULL
null	NULL
``	NULL
cell	NULL
leukemia	NULL
tends	NULL
to	NULL
contain	NULL
more	NULL
receptors	NULL
than	NULL
T-cell	NULL
leukemia	NULL
(	NULL
15	NULL
,	NULL
42	NULL
,	NULL
57	NULL
)	NULL
.3	NULL
The	NULL
correlation	NULL
with	NULL
the	NULL
immunological	NULL
type	NULL
appeared	NULL
less	NULL
striking	NULL
in	NULL
adults	NULL
(	NULL
7	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Few	NULL
data	NULL
are	NULL
available	NULL
concerning	NULL
B-cell	NULL
lineage	NULL
,	NULL
but	NULL
pre-B-cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
possess	NULL
as	NULL
many	NULL
receptors	NULL
as	NULL
``	NULL
null	NULL
``	NULL
cells	NULL
(	NULL
15	NULL
,	NULL
57	NULL
)	NULL
.	NULL

%	NULL
In	NULL
a	NULL
recent	NULL
study	NULL
,	NULL
GR	NULL
levels	NULL
were	NULL
measured	NULL
in	NULL
bone	NULL
marrow	NULL
aspirates	NULL
of	NULL
174	NULL
children	NULL
with	NULL
newly	NULL
diagnosed	NULL
ALL	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Bone	NULL
marrow	NULL
samples	NULL
were	NULL
selected	NULL
with	NULL
more	NULL
than	NULL
90	NULL
%	NULL
of	NULL
blast	NULL
cells	NULL
be-cause	NULL
,	NULL
as	NULL
mentioned	NULL
above	NULL
,	NULL
normal	NULL
bone	NULL
marrow	NULL
exhibits	NULL
a	NULL
high	NULL
level	NULL
of	NULL
GR	NULL
.	NULL

The	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
ranged	NULL
from	NULL
2,248	NULL
to	NULL
79,664	NULL
per	NULL
cell	NULL
(	NULL
median	NULL
,	NULL
18,123	NULL
)	NULL
and	NULL
was	NULL
higher	NULL
than	NULL
that	NULL
reported	NULL
previously	NULL
in	NULL
blood	NULL
samples	NULL
.	NULL

The	NULL
authors	NULL
suggested	NULL
that	NULL
this	NULL
discrepancy	NULL
may	NULL
result	NULL
either	NULL
from	NULL
cell	NULL
storage	NULL
(	NULL
GR	NULL
are	NULL
relatively	NULL
labile	NULL
)	NULL
or	NULL
from	NULL
a	NULL
true	NULL
difference	NULL
between	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
receptor	NULL
content	NULL
.	NULL

Extensive	NULL
comparative	NULL
studies	NULL
of	NULL
GR	NULL
levels	NULL
in	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
samples	NULL
need	NULL
to	NULL
be	NULL
performed	NULL
,	NULL
to	NULL
give	NULL
a	NULL
definite	NULL
answer	NULL
(	NULL
8	NULL
,	NULL
13	NULL
)	NULL
.	NULL

As	NULL
in	NULL
blood	NULL
,	NULL
GR	NULL
content	NULL
is	NULL
lower	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
T-cell	NULL
leukemia	NULL
than	NULL
in	NULL
that	NULL
of	NULL
common	NULL
leukemia	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
studies	NULL
with	NULL
a	NULL
limited	NULL
number	NULL
of	NULL
patients	NULL
,	NULL
no	NULL
significant	NULL
correlation	NULL
has	NULL
been	NULL
found	NULL
between	NULL
GR	NULL
content	NULL
of	NULL
circulating	NULL
cells	NULL
and	NULL
WBC	NULL
or	NULL
sex	NULL
(	NULL
33	NULL
,	NULL
37	NULL
,	NULL
42	NULL
,	NULL
49	NULL
)	NULL
.	NULL

However	NULL
,	NULL
after	NULL
studying	NULL
a	NULL
large	NULL
number	NULL
of	NULL
cases	NULL
,	NULL
Costlow	NULL
et	NULL
al	NULL
.	NULL

related	NULL
low	NULL
GR	NULL
levels	NULL
in	NULL
bone	NULL
marrow	NULL
to	NULL
ages	NULL
<	NULL
2	NULL
or	NULL
>	NULL
10	NULL
years	NULL
,	NULL
black	NULL
race	NULL
,	NULL
high	NULL
leukocyte	NULL
count	NULL
,	NULL
central	NULL
nervous	NULL
system	NULL
dis-ease	NULL
,	NULL
and	NULL
mediastinal	NULL
mass	NULL
;	NULL
all	NULL
these	NULL
parameters	NULL
are	NULL
recognized	NULL
as	NULL
high-risk	NULL
features	NULL
in	NULL
the	NULL
diagnosis	NULL
of	NULL
leukemia	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Attempts	NULL
to	NULL
correlate	NULL
the	NULL
level	NULL
of	NULL
GR	NULL
in	NULL
ALL	NULL
with	NULL
most	NULL
of	NULL
the	NULL
parameters	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
sensitivity	NULL
were	NULL
unsuccessful	NULL
in	NULL
most	NULL
of	NULL
the	NULL
studies	NULL
(	NULL
14	NULL
,	NULL
30	NULL
,	NULL
33	NULL
,	NULL
37	NULL
,	NULL
50	NULL
)	NULL
.	NULL

It	NULL
may	NULL
be	NULL
possible	NULL
to	NULL
explain	NULL
the	NULL
absence	NULL
of	NULL
correlation	NULL
between	NULL
the	NULL
number	NULL
of	NULL
receptors	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
steroids	NULL
by	NULL
the	NULL
heterogeneity	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
separated	NULL
our	NULL
patients	NULL
into	NULL
2	NULL
groups	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
blood	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
using	NULL
pulse	NULL
cytophotometry	NULL
analysis	NULL
(	NULL
33	NULL
)	NULL
.	NULL

it	NULL
appeared	NULL
that	NULL
the	NULL
in	NULL
vitro	NULL
inhibitory	NULL
effect	NULL
of	NULL
dexamethasone	NULL
was	NULL
2	NULL
times	NULL
higher	NULL
in	NULL
the	NULL
group	NULL
of	NULL
patients	NULL
with	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
than	NULL
in	NULL
the	NULL
group	NULL
of	NULL
patients	NULL
without	NULL
detectable	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
.	NULL

The	NULL
cytotoxic	NULL
effect	NULL
of	NULL
cortisol	NULL
was	NULL
recently	NULL
studied	NULL
in	NULL
different	NULL
types	NULL
of	NULL
ALL	NULL
defined	NULL
by	NULL
monoclonal	NULL
antibodies	NULL
and	NULL
rosettes	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Lymphoid	NULL
ceils	NULL
from	NULL
20	NULL
patients	NULL
with	NULL
common	NULL
ALL	NULL
were	NULL
found	NULL
to	NULL
be	NULL
resistant	NULL
to	NULL
cortisol	NULL
,	NULL
whereas	NULL
the	NULL
cells	NULL
from	NULL
10	NULL
patients	NULL
with	NULL
pre-B-leukemia	NULL
were	NULL
readily	NULL
lysed	NULL
.	NULL

Cells	NULL
from	NULL
5	NULL
patients	NULL
with	NULL
``	NULL
early	NULL
``	NULL
T-cell	NULL
leukemia	NULL
were	NULL
sensitive	NULL
,	NULL
whereas	NULL
cells	NULL
from	NULL
2	NULL
patients	NULL
with	NULL
a	NULL
more	NULL
mature	NULL
T-cell	NULL
phenotype	NULL
were	NULL
found	NULL
to	NULL
be	NULL
resistant	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
in	NULL
vitro	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
in	NULL
terms	NULL
of	NULL
cell	NULL
lysis	NULL
may	NULL
be	NULL
linked	NULL
to	NULL
cell	NULL
differentiation	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

GR	NULL
and	NULL
Sensitivity	NULL
in	NULL
Human	NULL
Lymphoid	NULL
Tissues	NULL
Table	NULL
2	NULL
Number	NULL
of	NULL
GR	NULL
in	NULL
normal	NULL
human	NULL
lymphoid	NULL
cells	NULL
(	NULL
whole-cell	NULL
assay	NULL
)	NULL
No	NULL
.	NULL

of	NULL
Cell	NULL
type	NULL
GR	NULL
Ky	NULL
(	NULL
M	NULL
)	NULL
patients	NULL
Refs	NULL
.	NULL

Children	NULL
's	NULL
bone	NULL
marrow	NULL
13.929	NULL
``	NULL
9	NULL
13	NULL
Children	NULL
's	NULL
thymocytes	NULL
3,100	NULL
5x	NULL
10	NULL
9	NULL
32	NULL
Adult	NULL
peripheral	NULL
lymphocytes	NULL
PBL	NULL
2,700	NULL
``	NULL
5.5	NULL
x	NULL
10°	NULL
10	NULL
58	NULL
Non-T-cell	NULL
2,892	NULL
+	NULL
1,068	NULL
``	NULL
4	NULL
x	NULL
10	NULL
4	NULL
46	NULL
T-cell	NULL
3,130	NULL
+	NULL
1,316	NULL
3.5	NULL
x	NULL
10~*	NULL
5	NULL
46	NULL
PBL	NULL
3,151+	NULL
726	NULL
71	NULL
x	NULL
10~*	NULL
7	NULL
70	NULL
T	NULL
+	NULL
null	NULL
4,680	NULL
5.6	NULL
x	NULL
10	NULL
%	NULL
5	NULL
36	NULL
B-celt	NULL
3,650	NULL
5.1	NULL
x	NULL
10~*	NULL
3	NULL
36	NULL
PBL	NULL
3,875	NULL
18	NULL
43	NULL
PBL	NULL
4,850	NULL
+	NULL
1,340	NULL
14	NULL
31	NULL
PBL	NULL
7.069	NULL
+	NULL
682	NULL
18	NULL
56	NULL
PBL	NULL
6,617+	NULL
979	NULL
4.8	NULL
x	NULL
10°	NULL
9	NULL
63	NULL
Adult	NULL
lymph	NULL
nodes	NULL
2,082	NULL
``	NULL
11	NULL
5	NULL
a	NULL
®	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

Table	NULL
3	NULL
Glucocorticoid	NULL
sensitivity	NULL
of	NULL
normal	NULL
human	NULL
lymphoid	NULL
cells	NULL
in	NULL
vitro	NULL
Inhibition	NULL
of	NULL
Inhibition	NULL
of	NULL
Cell	NULL
HJuridine	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
viability	NULL
incorporation	NULL
incorporation	NULL
Experimental	NULL
conditions	NULL
(	NULL
%	NULL
)	NULL
Refs	NULL
.	NULL

Experimental	NULL
conditions	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
Refs	NULL
.	NULL

Thymocytes	NULL
Cortisol	NULL
succinate	NULL
,	NULL
1	NULL
mg/m	NULL
!	NULL

,	NULL
>	NULL
90	NULL
26	NULL
Dexamethasone	NULL
,	NULL
10	NULL
®	NULL
m	NULL
,	NULL
701+	NULL
81°	NULL
959+	NULL
3.9	NULL
32	NULL
20	NULL
hr	NULL
24	NULL
hr	NULL
Peripheral	NULL
lymphocytes	NULL
Cortisol	NULL
succinate	NULL
,	NULL
10	NULL
g/ml	NULL
,	NULL
>	NULL
60	NULL
65	NULL
Dexamethasone	NULL
,	NULL
10	NULL
*	NULL
m	NULL
,	NULL
20.4	NULL
+	NULL
12.9	NULL
23.8	NULL
+	NULL
19.3	NULL
36	NULL
4	NULL
days	NULL
24	NULL
hr	NULL
Lymph	NULL
node	NULL
lymphocytes	NULL
Dexamethasone	NULL
,	NULL
4	NULL
x	NULL
107	NULL
``	NULL
m	NULL
,	NULL
>	NULL
80	NULL
5	NULL
Dexamethasone	NULL
,	NULL
107	NULL
``	NULL
m	NULL
,	NULL
28	NULL
21	NULL
5	NULL
4	NULL
days	NULL
20	NULL
hr	NULL
*	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

Table	NULL
4	NULL
Number	NULL
of	NULL
GR	NULL
in	NULL
ALL	NULL
(	NULL
whole-cell	NULL
assay	NULL
)	NULL
No	NULL
.	NULL

of	NULL
Patients	NULL
Type	NULL
of	NULL
leukemia	NULL
Sites/cell	NULL
Ky	NULL
(	NULL
M	NULL
)	NULL
patients	NULL
Refs	NULL
.	NULL

Blood	NULL
Children	NULL
Null	NULL
2,936-21,869	NULL
3.9	NULL
x	NULL
10°	NULL
27	NULL
42	NULL
T	NULL
0-5,887	NULL
3.9	NULL
x	NULL
10°	NULL
18	NULL
Children	NULL
+	NULL
adults	NULL
Null	NULL
+	NULL
B	NULL
+	NULL
T	NULL
2,560-19,160	NULL
3.9	NULL
x	NULL
10	NULL
%	NULL
23	NULL
33	NULL
Children	NULL
688-20,791	NULL
§	NULL
x	NULL
10~*	NULL
19	NULL
37	NULL
Children	NULL
Null	NULL
19,768	NULL
12	NULL
T	NULL
4,077	NULL
1	NULL
57	NULL
B	NULL
2,850	NULL
2	NULL
Children	NULL
+	NULL
adults	NULL
|_	NULL
Null	NULL
13,579	NULL
+11,434°	NULL
29	NULL
49	NULL
T+B	NULL
4171.6	NULL
+	NULL
2,517.3	NULL
8	NULL
Children	NULL
Pre-B	NULL
21,000	NULL
10	NULL
Null	NULL
14,000	NULL
14	NULL
15	NULL
T	NULL
2,500	NULL
9	NULL
Adults	NULL
Null	NULL
+	NULL
T	NULL
1,348-18,697	NULL
14	NULL
8	NULL
Children	NULL
+	NULL
adults	NULL
Common	NULL
+	NULL
B	NULL
+	NULL
T	NULL
1,433-26,858	NULL
7.7-46.1	NULL
x	NULL
10°	NULL
19	NULL
30	NULL
Children	NULL
+	NULL
adults	NULL
Null	NULL
+	NULL
B	NULL
+	NULL
T	NULL
8,495	NULL
+1,621	NULL
10	NULL
%	NULL
8	NULL
56	NULL
Children	NULL
Common	NULL
9,100	NULL
£7,500	NULL
87	NULL
Pre-B	NULL
8,000	NULL
+5,400	NULL
33	NULL
b	NULL
T	NULL
4,200	NULL
£3,100	NULL
20	NULL
Bone	NULL
marrow	NULL
Children	NULL
Common	NULL
2,480-79,364	NULL
(	NULL
21,329	NULL
``	NULL
)	NULL
122	NULL
T	NULL
9,016-37,072	NULL
(	NULL
9,016°	NULL
)	NULL
35	NULL
13	NULL
B	NULL
1,115-8,872	NULL
(	NULL
5,897°	NULL
)	NULL
5	NULL
Undifferentiated	NULL
9,265-29,574	NULL
(	NULL
20,992°	NULL
)	NULL
11	NULL
*	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

®	NULL
See	NULL
Footnote	NULL
3	NULL
.	NULL

©	NULL
Numbers	NULL
in	NULL
parentheses	NULL
,	NULL
median	NULL
.	NULL

FEBRUARY	NULL
1984	NULL
433	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

F.	NULL
Homo-Delarche	NULL
Antileukemic	NULL
therapy	NULL
usually	NULL
includes	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
glucocor-ticoids	NULL
,	NULL
2	NULL
or	NULL
3	NULL
other	NULL
cytotoxic	NULL
agents	NULL
,	NULL
and	NULL
it	NULL
is	NULL
therefore	NULL
difficult	NULL
to	NULL
ascertain	NULL
the	NULL
clinical	NULL
efficiency	NULL
of	NULL
one	NULL
of	NULL
these	NULL
drugs	NULL
and	NULL
to	NULL
relate	NULL
an	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
the	NULL
level	NULL
of	NULL
GR	NULL
.	NULL

To	NULL
overcome	NULL
this	NULL
difficulty	NULL
,	NULL
several	NULL
groups	NULL
have	NULL
attempted	NULL
to	NULL
correlate	NULL
the	NULL
level	NULL
of	NULL
receptors	NULL
with	NULL
the	NULL
short-term	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

By	NULL
selecting	NULL
the	NULL
responsive	NULL
patients	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
at	NULL
least	NULL
a	NULL
50	NULL
%	NULL
decrease	NULL
in	NULL
the	NULL
number	NULL
of	NULL
circulating	NULL
blast	NULL
cells	NULL
,	NULL
the	NULL
number	NULL
of	NULL
receptors	NULL
appeared	NULL
to	NULL
be	NULL
slightly	NULL
higher	NULL
in	NULL
the	NULL
sensitive	NULL
patients	NULL
(	NULL
8	NULL
,	NULL
30	NULL
,	NULL
33	NULL
,	NULL
37	NULL
,	NULL
49	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
Lippman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
48	NULL
)	NULL
were	NULL
the	NULL
first	NULL
to	NULL
compare	NULL
in	NULL
children	NULL
the	NULL
levels	NULL
of	NULL
receptors	NULL
at	NULL
diagnosis	NULL
before	NULL
any	NULL
treatment	NULL
with	NULL
long-term	NULL
combined	NULL
chemotherapy	NULL
.	NULL

They	NULL
showed	NULL
that	NULL
patients	NULL
with	NULL
high	NULL
receptor	NULL
levels	NULL
tend	NULL
to	NULL
have	NULL
``	NULL
null	NULL
``	NULL
cell	NULL
ALL	NULL
and	NULL
a	NULL
long	NULL
remission	NULL
duration	NULL
.	NULL

Patients	NULL
with	NULL
low	NULL
receptor	NULL
levels	NULL
have	NULL
T-tymphoblasts	NULL
and	NULL
a	NULL
short	NULL
remission	NULL
duration	NULL
.	NULL

Patients	NULL
with	NULL
intermediate	NULL
receptor	NULL
levels	NULL
had	NULL
an	NULL
intermediate	NULL
and	NULL
identical	NULL
remission	NULL
duration	NULL
,	NULL
regardless	NULL
of	NULL
the	NULL
cell	NULL
type	NULL
.	NULL

They	NULL
concluded	NULL
that	NULL
GR	NULL
levels	NULL
appear	NULL
to	NULL
have	NULL
clinical	NULL
significance	NULL
independently	NULL
of	NULL
age	NULL
,	NULL
WBC	NULL
,	NULL
or	NULL
cell	NULL
type	NULL
and	NULL
may	NULL
represent	NULL
a	NULL
biological	NULL
marker	NULL
associated	NULL
with	NULL
other	NULL
factors	NULL
,	NULL
which	NULL
are	NULL
related	NULL
to	NULL
chemotherapy	NULL
response	NULL
,	NULL
such	NULL
as	NULL
rate	NULL
of	NULL
growth	NULL
or	NULL
biochemical	NULL
differentiation	NULL
.	NULL

More	NULL
recent	NULL
studies	NULL
in	NULL
children	NULL
confirmed	NULL
that	NULL
low	NULL
GR	NULL
levels	NULL
are	NULL
associated	NULL
with	NULL
earlier	NULL
and	NULL
more	NULL
frequent	NULL
relapse	NULL
(	NULL
13	NULL
,	NULL
31	NULL
,	NULL
49	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
GR	NULL
levels	NULL
did	NULL
not	NULL
correlate	NULL
with	NULL
response	NULL
to	NULL
combined	NULL
chemotherapy	NULL
,	NULL
duration	NULL
of	NULL
remission	NULL
,	NULL
or	NULL
survival	NULL
in	NULL
adults	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Chronic	NULL
Lymphocytic	NULL
Leukemia	NULL
Determinations	NULL
of	NULL
GR	NULL
have	NULL
now	NULL
been	NULL
performed	NULL
by	NULL
several	NULL
groups	NULL
in	NULL
more	NULL
than	NULL
100	NULL
patients	NULL
with	NULL
CLL	NULL
(	NULL
24	NULL
,	NULL
31	NULL
,	NULL
35	NULL
,	NULL
43	NULL
,	NULL
56	NULL
,	NULL
67	NULL
,	NULL
69	NULL
,	NULL
71	NULL
,	NULL
72	NULL
,	NULL
74	NULL
)	NULL
.	NULL

In	NULL
the	NULL
early	NULL
studies	NULL
performed	NULL
by	NULL
cytosolic	NULL
assay	NULL
,	NULL
the	NULL
receptors	NULL
were	NULL
detected	NULL
in	NULL
only	NULL
one-half	NULL
to	NULL
one-third	NULL
of	NULL
the	NULL
patients	NULL
.	NULL

Again	NULL
,	NULL
when	NULL
assayed	NULL
by	NULL
whole-cell	NULL
assay	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
glucoceorticoid-binding	NULL
sites	NULL
was	NULL
detected	NULL
in	NULL
all	NULL
cases	NULL
.	NULL

The	NULL
number	NULL
of	NULL
these	NULL
receptors	NULL
was	NULL
on	NULL
an	NULL
average	NULL
similar	NULL
to	NULL
or	NULL
even	NULL
slightly	NULL
lower	NULL
than	NULL
that	NULL
measured	NULL
in	NULL
normal	NULL
PBL	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

(	NULL
31	NULL
)	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
cells	NULL
from	NULL
patients	NULL
who	NULL
were	NULL
treated	NULL
for	NULL
3	NULL
to	NULL
5	NULL
years	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
corticoids	NULL
and	NULL
chlorambucil	NULL
and	NULL
became	NULL
resistant	NULL
to	NULL
this	NULL
treatment	NULL
contain	NULL
lower	NULL
receptor	NULL
content	NULL
than	NULL
did	NULL
cells	NULL
from	NULL
newly	NULL
diagnosed	NULL
patients	NULL
.	NULL

Attempts	NULL
made	NULL
to	NULL
correlate	NULL
the	NULL
amount	NULL
of	NULL
receptors	NULL
with	NULL
in	NULL
vitro	NULL
steroid	NULL
sensitivity	NULL
were	NULL
unsuccessful	NULL
(	NULL
14	NULL
,	NULL
31	NULL
,	NULL
35	NULL
,	NULL
71	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
,	NULL
however	NULL
,	NULL
that	NULL
the	NULL
extent	NULL
of	NULL
dexamethasone-induced	NULL
inhibition	NULL
of	NULL
uridine	NULL
incorporation	NULL
was	NULL
generally	NULL
more	NULL
important	NULL
in	NULL
cells	NULL
from	NULL
CLL	NULL
patients	NULL
than	NULL
in	NULL
normal	NULL
PBL	NULL
and	NULL
that	NULL
this	NULL
in	NULL
vitro	NULL
steroid	NULL
sensitivity	NULL
increased	NULL
significantly	NULL
with	NULL
the	NULL
severity	NULL
Table	NULL
5	NULL
Number	NULL
of	NULL
GR	NULL
in	NULL
CLL	NULL
(	NULL
whole-cell	NULL
assay	NULL
)	NULL
No	NULL
.	NULL

of	NULL
Sites/cell	NULL
patients	NULL
Refs	NULL
.	NULL

Total	NULL
binding	NULL
4000-6000	NULL
21	NULL
35	NULL
3423	NULL
+	NULL
666°	NULL
``	NULL
17	NULL
69	NULL
3850	NULL
+	NULL
773	NULL
6	NULL
43	NULL
4500	NULL
11	NULL
31	NULL
2912	NULL
+	NULL
884	NULL
6	NULL
56	NULL
Nuclear	NULL
binding	NULL
2032+	NULL
69	NULL
14	NULL
72	NULL
2119	NULL
12	NULL
14	NULL
*	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

434	NULL
of	NULL
the	NULL
iliness	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
CLL	NULL
lymphocytes	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
normal	NULL
PBL	NULL
,	NULL
were	NULL
in	NULL
vitro	NULL
very	NULL
sensitive	NULL
to	NULL
the	NULL
cytotoxic	NULL
action	NULL
of	NULL
glucocorticoids	NULL
(	NULL
26	NULL
,	NULL
66	NULL
)	NULL
.	NULL

Hairy	NULL
Cell	NULL
Leukemia	NULL
GR	NULL
were	NULL
measured	NULL
by	NULL
whole-cell	NULL
assay	NULL
in	NULL
leukemic	NULL
cells	NULL
from	NULL
5	NULL
patients	NULL
with	NULL
hairy	NULL
cell	NULL
leukemia	NULL
(	NULL
44	NULL
)	NULL
.	NULL

GR	NULL
sites	NULL
ranged	NULL
from	NULL
5,710	NULL
to	NULL
11,400	NULL
sites	NULL
per	NULL
cell	NULL
,	NULL
with	NULL
a	NULL
K	NULL
,	NULL
of	NULL
about	NULL
107°	NULL
m.	NULL
Glucocorticoid	NULL
sensitivity	NULL
studied	NULL
in	NULL
a	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
one	NULL
of	NULL
the	NULL
patients	NULL
showed	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
a	NULL
stimulation	NULL
of	NULL
DNA	NULL
synthesis	NULL
.	NULL

Non-Hodgkin	NULL
's	NULL
Malignant	NULL
Lymphoma	NULL
Investigations	NULL
of	NULL
malignant	NULL
lymph	NULL
nodes	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
cell	NULL
suspensions	NULL
containing	NULL
at	NULL
least	NULL
50	NULL
%	NULL
malignant	NULL
cells	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
measured	NULL
by	NULL
whole-cell	NULL
assay	NULL
varied	NULL
greatly	NULL
from	NULL
one	NULL
patient	NULL
to	NULL
another	NULL
but	NULL
was	NULL
on	NULL
an	NULL
average	NULL
higher	NULL
in	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
non-Hodgkin	NULL
's	NULL
malignant	NULL
lymphoma	NULL
than	NULL
in	NULL
cells	NULL
isolated	NULL
from	NULL
control	NULL
lymph	NULL
nodes	NULL
[	NULL
median	NULL
values	NULL
are	NULL
4110	NULL
(	NULL
n	NULL
=	NULL
42	NULL
)	NULL
and	NULL
2082	NULL
(	NULL
n	NULL
=	NULL
11	NULL
)	NULL
sites	NULL
per	NULL
cell	NULL
,	NULL
respec-tively	NULL
]	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
``	NULL
null	NULL
``	NULL
cell	NULL
as	NULL
in	NULL
ALL	NULL
patients	NULL
,	NULL
usually	NULL
contained	NULL
more	NULL
receptors	NULL
than	NULL
did	NULL
T-cell	NULL
Iymphomas	NULL
.	NULL

Finally	NULL
,	NULL
sequential	NULL
investigations	NULL
(	NULL
at	NULL
diagnosis	NULL
and	NULL
at	NULL
relapse	NULL
)	NULL
showed	NULL
a	NULL
decrease	NULL
of	NULL
the	NULL
number	NULL
of	NULL
GR	NULL
after	NULL
treatment	NULL
.	NULL

Despite	NULL
the	NULL
high	NULL
sensitivity	NULL
of	NULL
Iymphoma	NULL
cells	NULL
to	NULL
the	NULL
cytotoxic	NULL
action	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
(	NULL
almost	NULL
50	NULL
%	NULL
of	NULL
cell	NULL
lysis	NULL
after	NULL
96	NULL
hr	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
4	NULL
x	NULL
10~	NULL
``	NULL
m	NULL
dexamethasone	NULL
)	NULL
,	NULL
no	NULL
correlation	NULL
could	NULL
be	NULL
found	NULL
between	NULL
the	NULL
level	NULL
of	NULL
these	NULL
GR	NULL
and	NULL
any	NULL
parameters	NULL
of	NULL
in	NULL
vitro	NULL
sensitivity	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
Bloomfield	NULL
et	NULL
al	NULL
.	NULL

(	NULL
5	NULL
)	NULL
have	NULL
studied	NULL
in	NULL
20	NULL
patients	NULL
the	NULL
response	NULL
to	NULL
therapy	NULL
with	NULL
corticosteroids	NULL
as	NULL
a	NULL
single	NULL
agent	NULL
.	NULL

They	NULL
showed	NULL
in	NULL
the	NULL
group	NULL
of	NULL
responders	NULL
(	NULL
with	NULL
a	NULL
50	NULL
%	NULL
or	NULL
more	NULL
decrease	NULL
in	NULL
measurable	NULL
tumor	NULL
after	NULL
corticotherapy	NULL
)	NULL
that	NULL
the	NULL
number	NULL
of	NULL
GR	NULL
was	NULL
significantly	NULL
higher	NULL
than	NULL
in	NULL
nonresponders	NULL
(	NULL
5600	NULL
versus	NULL
3300	NULL
sites	NULL
,	NULL
p	NULL
<	NULL
0.01	NULL
,	NULL
n	NULL
=	NULL
10	NULL
,	NULL
in	NULL
each	NULL
group	NULL
)	NULL
.	NULL

Thymoma	NULL
Ranelletti	NULL
et	NULL
al	NULL
.	NULL

(	NULL
37	NULL
,	NULL
60	NULL
,	NULL
61	NULL
)	NULL
have	NULL
studied	NULL
the	NULL
level	NULL
of	NULL
GR	NULL
in	NULL
various	NULL
forms	NULL
of	NULL
thymus	NULL
dysplasia	NULL
.	NULL

Using	NULL
a	NULL
cytosolic	NULL
assay	NULL
,	NULL
they	NULL
showed	NULL
that	NULL
the	NULL
level	NULL
of	NULL
specific	NULL
receptors	NULL
was	NULL
significantly	NULL
higher	NULL
in	NULL
Iymphoepithelial	NULL
thymoma	NULL
than	NULL
in	NULL
pure	NULL
epithelial	NULL
form	NULL
,	NULL
in	NULL
thymus	NULL
hyperplasia	NULL
,	NULL
or	NULL
even	NULL
in	NULL
normal	NULL
thymus	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
this	NULL
high	NULL
level	NULL
of	NULL
GR	NULL
,	NULL
the	NULL
in	NULL
vitro	NULL
sensitivity	NULL
of	NULL
thymoma	NULL
cells	NULL
to	NULL
glucosteroids	NULL
was	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
normal	NULL
thymus	NULL
cells	NULL
either	NULL
in	NULL
terms	NULL
of	NULL
inhibition	NULL
of	NULL
precursor	NULL
incorporation	NULL
or	NULL
in	NULL
terms	NULL
of	NULL
steroid-induced	NULL
cell	NULL
lysis	NULL
.	NULL

Sézary	NULL
Syndrome	NULL
Schmidt	NULL
and	NULL
Thompson	NULL
(	NULL
64	NULL
)	NULL
have	NULL
studied	NULL
the	NULL
binding	NULL
of	NULL
tritiated	NULL
dexamethasone	NULL
in	NULL
the	NULL
circulating	NULL
lymphocytes	NULL
of	NULL
7	NULL
patients	NULL
with	NULL
Sézary	NULL
syndrome	NULL
.	NULL

Using	NULL
a	NULL
cytosolic	NULL
assay	NULL
,	NULL
they	NULL
showed	NULL
the	NULL
presence	NULL
of	NULL
detectable	NULL
specific	NULL
receptors	NULL
in	NULL
5	NULL
cases	NULL
.	NULL

Although	NULL
one	NULL
patient	NULL
with	NULL
very	NULL
high	NULL
levels	NULL
of	NULL
receptors	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
dramatically	NULL
improved	NULL
by	NULL
prednisone	NULL
treatment	NULL
,	NULL
whereas	NULL
one	NULL
patient	NULL
with	NULL
no	NULL
detectable	NULL
receptors	NULL
was	NULL
refractory	NULL
to	NULL
combined	NULL
chemotherapy	NULL
,	NULL
it	NULL
also	NULL
appears	NULL
that	NULL
2	NULL
patients	NULL
with	NULL
nonnegligible	NULL
levels	NULL
of	NULL
receptors	NULL
were	NULL
not	NULL
sensitive	NULL
to	NULL
combined	NULL
chemotherapy	NULL
including	NULL
glucocorticoids	NULL
.	NULL

These	NULL
authors	NULL
also	NULL
proposed	NULL
that	NULL
the	NULL
determination	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
steroid	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

inducible	NULL
enzyme	NULL
glutamine	NULL
synthetase	NULL
might	NULL
represent	NULL
a	NULL
useful	NULL
test	NULL
for	NULL
functional	NULL
glucocorticoid	NULL
action	NULL
.	NULL

Discussion	NULL
After	NULL
10	NULL
years	NULL
of	NULL
research	NULL
in	NULL
GR	NULL
and	NULL
leukemia	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
discrepancies	NULL
seen	NULL
among	NULL
the	NULL
results	NULL
of	NULL
the	NULL
various	NULL
studies	NULL
may	NULL
be	NULL
in	NULL
part	NULL
accounted	NULL
for	NULL
by	NULL
differences	NULL
in	NULL
the	NULL
selection	NULL
of	NULL
the	NULL
patients	NULL
and	NULL
the	NULL
experimental	NULL
procedures	NULL
used	NULL
to	NULL
determine	NULL
receptor	NULL
levels	NULL
.	NULL

Selection	NULL
of	NULL
the	NULL
Patients	NULL
and	NULL
Target	NULL
Tissue	NULL
For	NULL
experimental	NULL
convenience	NULL
,	NULL
most	NULL
of	NULL
the	NULL
studies	NULL
have	NULL
been	NULL
performed	NULL
using	NULL
peripheral	NULL
leukocytes	NULL
,	NULL
although	NULL
it	NULL
is	NULL
now	NULL
well	NULL
recognized	NULL
that	NULL
blood	NULL
cells	NULL
do	NULL
not	NULL
entirely	NULL
reflect	NULL
the	NULL
proliferative	NULL
activity	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
comparative	NULL
studies	NULL
performed	NULL
in	NULL
the	NULL
same	NULL
patients	NULL
may	NULL
show	NULL
differences	NULL
in	NULL
GR	NULL
levels	NULL
between	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
samples	NULL
(	NULL
8	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Bone	NULL
marrow	NULL
,	NULL
which	NULL
is	NULL
usually	NULL
the	NULL
main	NULL
focus	NULL
of	NULL
tumoral	NULL
proliferation	NULL
,	NULL
may	NULL
thus	NULL
represent	NULL
a	NULL
more	NULL
appropriate	NULL
tissue	NULL
for	NULL
the	NULL
study	NULL
of	NULL
glucocorticoid	NULL
action	NULL
,	NULL
particularly	NULL
in	NULL
leukopenic	NULL
patients	NULL
.	NULL

When	NULL
the	NULL
patients	NULL
have	NULL
been	NULL
selected	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
more	NULL
than	NULL
80	NULL
to	NULL
90	NULL
%	NULL
of	NULL
circulating	NULL
or	NULL
bone	NULL
marrow	NULL
blast	NULL
cells	NULL
,	NULL
attempts	NULL
to	NULL
correlate	NULL
GR	NULL
levels	NULL
with	NULL
some	NULL
other	NULL
parameters	NULL
(	NULL
immunological	NULL
type	NULL
,	NULL
response	NULL
to	NULL
combined	NULL
chemotherapy	NULL
)	NULL
have	NULL
been	NULL
more	NULL
successful	NULL
.	NULL

Problems	NULL
of	NULL
Receptor	NULL
Determination	NULL
Besides	NULL
the	NULL
technical	NULL
problems	NULL
of	NULL
receptor	NULL
determination	NULL
,	NULL
which	NULL
have	NULL
already	NULL
been	NULL
underlined	NULL
(	NULL
storage	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
cytosol	NULL
versus	NULL
whole-cell	NULL
assay	NULL
)	NULL
,	NULL
it	NULL
should	NULL
be	NULL
kept	NULL
in	NULL
mind	NULL
that	NULL
receptor	NULL
concentration	NULL
in	NULL
a	NULL
given	NULL
target	NULL
cell	NULL
is	NULL
not	NULL
constant	NULL
.	NULL

It	NULL
may	NULL
vary	NULL
under	NULL
the	NULL
influence	NULL
of	NULL
several	NULL
factors	NULL
,	NULL
as	NULL
reviewed	NULL
elsewhere	NULL
(	NULL
18	NULL
,	NULL
45	NULL
)	NULL
,	NULL
and	NULL
in	NULL
particular	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
extracellular	NULL
concentration	NULL
of	NULL
glucocorticoids	NULL
(	NULL
2	NULL
,	NULL
22	NULL
,	NULL
28	NULL
,	NULL
34	NULL
,	NULL
63	NULL
,	NULL
73	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
the	NULL
patients	NULL
to	NULL
be	NULL
investigated	NULL
should	NULL
be	NULL
examined	NULL
at	NULL
diagnosis	NULL
before	NULL
any	NULL
corticoid	NULL
therapy	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
level	NULL
of	NULL
GR	NULL
in	NULL
the	NULL
previously	NULL
treated	NULL
patients	NULL
,	NULL
even	NULL
if	NULL
they	NULL
have	NULL
been	NULL
withdrawn	NULL
from	NULL
steroid	NULL
treatment	NULL
1	NULL
to	NULL
2	NULL
weeks	NULL
before	NULL
,	NULL
is	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
patients	NULL
at	NULL
diagnosis	NULL
(	NULL
5	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
Steroid	NULL
Sensitivity	NULL
Studies	NULL
performed	NULL
in	NULL
mouse	NULL
lymphoma	NULL
cell	NULL
lines	NULL
have	NULL
demonstrated	NULL
a	NULL
fairly	NULL
good	NULL
correlation	NULL
between	NULL
the	NULL
level	NULL
of	NULL
GR	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
action	NULL
of	NULL
steroids	NULL
(	NULL
40	NULL
,	NULL
62	NULL
)	NULL
.	NULL

Similar	NULL
investigations	NULL
carried	NULL
out	NULL
on	NULL
cells	NULL
taken	NULL
from	NULL
patients	NULL
failed	NULL
to	NULL
show	NULL
such	NULL
a	NULL
correlation	NULL
,	NULL
as	NULL
mentioned	NULL
above	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
was	NULL
demonstrated	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
receptor	NULL
levels	NULL
following	NULL
mitogen	NULL
treatment	NULL
was	NULL
not	NULL
associated	NULL
with	NULL
any	NULL
significant	NULL
alteration	NULL
of	NULL
in	NULL
vitro	NULL
steroid	NULL
effect	NULL
(	NULL
70	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
despite	NULL
the	NULL
general	NULL
assumption	NULL
that	NULL
steroid-induced	NULL
cell	NULL
death	NULL
represents	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
catabolic	NULL
actions	NULL
of	NULL
the	NULL
drug	NULL
,	NULL
there	NULL
is	NULL
no	NULL
relationship	NULL
between	NULL
the	NULL
extent	NULL
of	NULL
cell	NULL
lysis	NULL
and	NULL
the	NULL
metabolic	NULL
inhibition	NULL
(	NULL
34	NULL
,	NULL
59	NULL
)	NULL
.	NULL

It	NULL
should	NULL
,	NULL
however	NULL
,	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
in	NULL
vitro	NULL
inhibitory	NULL
action	NULL
of	NULL
glucocorticoids	NULL
was	NULL
more	NULL
marked	NULL
in	NULL
lymphoid	NULL
populations	NULL
characterized	NULL
by	NULL
a	NULL
high	NULL
level	NULL
of	NULL
proliferative	NULL
activity	NULL
(	NULL
32	NULL
,	NULL
33	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Recent	NULL
investigations	NULL
have	NULL
also	NULL
shown	NULL
that	NULL
the	NULL
in	NULL
vitro	NULL
action	NULL
of	NULL
steroids	NULL
on	NULL
lymphoid	NULL
cells	NULL
may	NULL
be	NULL
more	NULL
complex	NULL
than	NULL
previ-	NULL
FEBRUARY	NULL
1984	NULL
GR	NULL
and	NULL
Sensitivity	NULL
in	NULL
Human	NULL
Lymphoid	NULL
Tissues	NULL
ously	NULL
believed	NULL
.	NULL

Gillis	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
27	NULL
)	NULL
demonstrated	NULL
that	NULL
inhibition	NULL
of	NULL
mitogen-induced	NULL
cell	NULL
proliferation	NULL
by	NULL
steroids	NULL
represents	NULL
an	NULL
indirect	NULL
action	NULL
(	NULL
suppressing	NULL
the	NULL
production	NULL
of	NULL
a	NULL
T-cell	NULL
growth	NULL
factor	NULL
by	NULL
a	NULL
small	NULL
subset	NULL
of	NULL
cells	NULL
)	NULL
rather	NULL
than	NULL
a	NULL
direct	NULL
action	NULL
at	NULL
the	NULL
level	NULL
of	NULL
activated	NULL
lymphocyte	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
in	NULL
vitro	NULL
sensitivity	NULL
of	NULL
leukemic	NULL
blasts	NULL
may	NULL
not	NULL
always	NULL
reflect	NULL
the	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
combined	NULL
chemotherapy	NULL
.	NULL

We	NULL
have	NULL
already	NULL
seen	NULL
that	NULL
the	NULL
response	NULL
to	NULL
treatment	NULL
as	NULL
well	NULL
as	NULL
the	NULL
number	NULL
of	NULL
GR	NULL
appears	NULL
more	NULL
probably	NULL
dependent	NULL
on	NULL
the	NULL
immunological	NULL
type	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

It	NULL
was	NULL
recently	NULL
demonstrated	NULL
that	NULL
high	NULL
levels	NULL
of	NULL
GR	NULL
were	NULL
usually	NULL
associated	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
terminal	NULL
deoxynucleotidy	NULL
!	NULL

transferase	NULL
activity	NULL
in	NULL
lymphoid	NULL
as	NULL
well	NULL
as	NULL
in	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
(	NULL
55	NULL
,	NULL
68	NULL
)	NULL
.	NULL

Although	NULL
these	NULL
results	NULL
should	NULL
be	NULL
confirmed	NULL
in	NULL
more	NULL
extensive	NULL
studies	NULL
,	NULL
including	NULL
careful	NULL
choice	NULL
of	NULL
patients	NULL
and	NULL
investigation	NULL
of	NULL
immunological	NULL
markers	NULL
,	NULL
they	NULL
suggest	NULL
a	NULL
relationship	NULL
between	NULL
the	NULL
level	NULL
of	NULL
receptors	NULL
and	NULL
cell	NULL
differentiation	NULL
.	NULL

Evaluation	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
corticoid	NULL
therapy	NULL
is	NULL
even	NULL
more	NULL
complex	NULL
because	NULL
it	NULL
represents	NULL
a	NULL
combination	NULL
of	NULL
different	NULL
mechanisms	NULL
including	NULL
,	NULL
among	NULL
others	NULL
,	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
and	NULL
cell	NULL
lysis	NULL
,	NULL
but	NULL
also	NULL
cell	NULL
recirculation	NULL
and	NULL
sequestration	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
is	NULL
obvious	NULL
that	NULL
in	NULL
vivo	NULL
the	NULL
perturbations	NULL
caused	NULL
by	NULL
steroid	NULL
treatment	NULL
on	NULL
the	NULL
general	NULL
hormonal	NULL
balance	NULL
,	NULL
on	NULL
vascular	NULL
function	NULL
,	NULL
and	NULL
on	NULL
immunological	NULL
reactions	NULL
may	NULL
influence	NULL
considerably	NULL
the	NULL
evolution	NULL
of	NULL
leukemia	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
there	NULL
are	NULL
now	NULL
some	NULL
indications	NULL
suggesting	NULL
that	NULL
the	NULL
cells	NULL
of	NULL
ALL	NULL
sensitive	NULL
to	NULL
steroid	NULL
therapy	NULL
and/or	NULL
chemotherapy	NULL
tend	NULL
to	NULL
contain	NULL
more	NULL
receptor	NULL
than	NULL
do	NULL
cells	NULL
of	NULL
nonresponders	NULL
or	NULL
patients	NULL
who	NULL
will	NULL
relapse	NULL
.	NULL

Finally	NULL
,	NULL
there	NULL
are	NULL
several	NULL
aspects	NULL
of	NULL
steroid	NULL
action	NULL
which	NULL
have	NULL
not	NULL
been	NULL
fully	NULL
explored	NULL
but	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
neoplastic	NULL
lymphoid	NULL
tissues	NULL
.	NULL

Recent	NULL
findings	NULL
have	NULL
shown	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
high	NULL
level	NULL
of	NULL
transcortin	NULL
in	NULL
patients	NULL
with	NULL
lymphatic	NULL
leukemia	NULL
and	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
(	NULL
16	NULL
)	NULL
.	NULL

This	NULL
abnormality	NULL
was	NULL
associated	NULL
with	NULL
HLA	NULL
antigens	NULL
of	NULL
the	NULL
B	NULL
and	NULL
C	NULL
loci	NULL
.	NULL

These	NULL
results	NULL
,	NULL
together	NULL
with	NULL
the	NULL
indications	NULL
suggesting	NULL
that	NULL
GR	NULL
and	NULL
steroid	NULL
response	NULL
may	NULL
be	NULL
under	NULL
the	NULL
control	NULL
genetic	NULL
influence	NULL
(	NULL
3	NULL
,	NULL
9	NULL
,	NULL
29	NULL
)	NULL
,	NULL
raise	NULL
the	NULL
question	NULL
of	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
transcortin	NULL
in	NULL
the	NULL
modulation	NULL
of	NULL
GR	NULL
and	NULL
steroid	NULL
sensitivity	NULL
.	NULL

in	NULL
addition	NULL
,	NULL
several	NULL
authors	NULL
have	NULL
described	NULL
an	NULL
increased	NULL
metabolism	NULL
of	NULL
cortisol	NULL
in	NULL
malignant	NULL
lymphoid	NULL
cells	NULL
(	NULL
23	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Others	NULL
have	NULL
shown	NULL
a	NULL
relatively	NULL
higher	NULL
metabolism	NULL
of	NULL
cortisol	NULL
by	NULL
B-lymphocytes	NULL
than	NULL
by	NULL
T-lymphocytes	NULL
and	NULL
suggested	NULL
that	NULL
this	NULL
may	NULL
explain	NULL
the	NULL
greater	NULL
resistance	NULL
to	NULL
cortisol	NULL
of	NULL
B-cells	NULL
(	NULL
41	NULL
)	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
whether	NULL
this	NULL
phenomenon	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
GR	NULL
and/or	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
response	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Bach	NULL
,	NULL
J.	NULL
F.	NULL
Corticosteroids	NULL
.	NULL

Front	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
41	NULL
:	NULL
21	NULL
,	NULL
1975	NULL
.	NULL

2	NULL
.	NULL

Beato	NULL
,	NULL
M.	NULL
,	NULL
Kalimi	NULL
,	NULL
M.	NULL
,	NULL
Beato	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Feigelson	NULL
,	NULL
P.	NULL
Interaction	NULL
of	NULL
glucocorti-colds	NULL
with	NULL
rat	NULL
liver	NULL
nuclei	NULL
:	NULL
effect	NULL
of	NULL
adrenalectomy	NULL
and	NULL
cortisol	NULL
administration	NULL
.	NULL

Endocrinology	NULL
,	NULL
94	NULL
:	NULL
377-387	NULL
,	NULL
1974	NULL
.	NULL

3	NULL
.	NULL

Becker	NULL
,	NULL
B.	NULL
,	NULL
Shin	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Palmberg	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
and	NULL
Waltman	NULL
,	NULL
S.	NULL
R.	NULL
HLA	NULL
antigens	NULL
and	NULL
corticosteroid	NULL
response	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
D.	NULL
C.	NULL
)	NULL
,	NULL
194	NULL
:	NULL
1427-1428	NULL
,	NULL
1976	NULL
.	NULL

4	NULL
.	NULL

Bird	NULL
,	NULL
C.	NULL
C.	NULL
Clinical	NULL
classification	NULL
of	NULL
leukemia	NULL
and	NULL
lymphoma	NULL
in	NULL
relation	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

in	NULL
:	NULL
Glucocorticoid	NULL
Action	NULL
and	NULL
Leukemia	NULL
,	NULL
7th	NULL
Tenovus	NULL
Workshop	NULL
,	NULL
p.	NULL
123	NULL
.	NULL

Cardiff	NULL
,	NULL
Wales	NULL
:	NULL
Alpha	NULL
Omega	NULL
Publishing	NULL
,	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

5	NULL
.	NULL

Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hildebrandt	NULL
,	NULL
L.	NULL
,	NULL
Zaleskas	NULL
,	NULL
J.	NULL
,	NULL
Gail-Peczalska	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Frizzera	NULL
,	NULL
G.	NULL
,	NULL
Peterson	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Kersey	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A	NULL
.	NULL

The	NULL
therapeutic	NULL
utility	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
studies	NULL
in	NULL
non-Hodgkin	NULL
's	NULL
malignant	NULL
lymphoma	NULL
.	NULL

in	NULL
:	NULL
S.	NULL
lacobelii	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

B	NULL
.	NULL

King	NULL
,	NULL
H.	NULL
R.	NULL
Lindner	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Lippman	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Hormones	NULL
and	NULL
Cancer	NULL
,	NULL
p.	NULL
345	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1980	NULL
.	NULL

6	NULL
.	NULL

Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Peterson	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
U.	NULL
in	NULL
vitro	NULL
glucocorticoid	NULL
studies	NULL
in	NULL
human	NULL
lymphoma	NULL
:	NULL
clinical	NULL
and	NULL
biological	NULL
significance	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
15	NULL
:	NULL
275-284	NULL
,	NULL
1981	NULL
.	NULL

435	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

F.	NULL
Homo-Delarche	NULL
7	NULL
.	NULL

10	NULL
.	NULL

1	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Peterson	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Hildebrandt	NULL
,	NULL
L.	NULL
,	NULL
Zaleskas	NULL
,	NULL
J.	NULL
,	NULL
Gajl-Peczaiska	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Frizzera	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
in	NULL
vitro	NULL
glucocorticoid	NULL
studies	NULL
for	NULL
predicting	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
in	NULL
adults	NULL
with	NULL
malignant	NULL
lymphoma	NULL
.	NULL

Lancet	NULL
,	NULL
1	NULL
:	NULL
952-956	NULL
,	NULL
1980.	NULL
.	NULL

Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Peterson	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
adult	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
47	NULL
:	NULL
4857-4860	NULL
,	NULL
1981.	NULL
.	NULL

Butley	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Erickson	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B.	NULL
Hepatic	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
the	NULL
H	NULL
»	NULL
locus	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
275	NULL
:	NULL
136-138	NULL
,	NULL
1978	NULL
.	NULL

Caffey	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Silbey	NULL
,	NULL
R.	NULL
Regrowth	NULL
and	NULL
overgrowth	NULL
of	NULL
the	NULL
thymus	NULL
after	NULL
atrophy	NULL
induced	NULL
by	NULL
the	NULL
oral	NULL
administration	NULL
of	NULL
adrenocorticosteroids	NULL
to	NULL
human	NULL
infants	NULL
.	NULL

Pediatrics	NULL
,	NULL
26	NULL
:	NULL
762-770	NULL
,	NULL
1960	NULL
.	NULL

(	NULL
335mm	NULL
.	NULL

H.	NULL
N.	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
287	NULL
:	NULL
388-7	NULL
,	NULL
1972	NULL
.	NULL

Claman	NULL
,	NULL
H.	NULL
N.	NULL
,	NULL
Moorhead	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Benner	NULL
,	NULL
W.	NULL
H.	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

I.	NULL
Hydrooorusone	NULL
lysis	NULL
of	NULL
human	NULL
,	NULL
guinea	NULL
pig	NULL
,	NULL
and	NULL
mouse	NULL
thymus	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Lab	NULL
.	NULL

Clin	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
78	NULL
:	NULL
499-507	NULL
,	NULL
1971	NULL
.	NULL

Costlow	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Ching-Hon	NULL
Pui	NULL
,	NULL
and	NULL
Dahi	NULL
,	NULL
G.	NULL
V.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
childhood	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
42	NULL
:	NULL
4801-4806	NULL
,	NULL
1982	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
/n	NULL
vitro	NULL
sensitivity	NULL
of	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
leukemia	NULL
and	NULL
lymphoma	NULL
:	NULL
a	NULL
reas-	NULL
sessment	NULL
.	NULL

/n	NULL
:	NULL
Glucocorticoid	NULL
Action	NULL
and	NULL
Leukemia	NULL
.	NULL

7th	NULL
Tenovus	NULL
Workshop	NULL
,	NULL
p.	NULL
191	NULL
.	NULL

Cardiff	NULL
,	NULL
Wales	NULL
:	NULL
Alpha	NULL
Omega	NULL
Publishing	NULL
,	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

Crist	NULL
,	NULL
W.	NULL
,	NULL
Vogler	NULL
,	NULL
L.	NULL
,	NULL
Sarrif	NULL
,	NULL
A.	NULL
,	NULL
Pullen	NULL
,	NULL
J.	NULL
,	NULL
Bartolucci	NULL
,	NULL
A.	NULL
,	NULL
Falleta	NULL
,	NULL
J.	NULL
,	NULL
Humphrey	NULL
,	NULL
B.	NULL
,	NULL
Ban	NULL
Eys	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Copper	NULL
,	NULL
M.	NULL
Clinical	NULL
and	NULL
laboratory	NULL
characterization	NULL
of	NULL
a	NULL
pre-B	NULL
cell	NULL
leukemia	NULL
in	NULL
children	NULL
.	NULL

Blood	NULL
,	NULL
54	NULL
(	NULL
Suppl	NULL
.	NULL
)	NULL

183a	NULL
,	NULL
1979	NULL
.	NULL

De	NULL
Moor	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Louwagie	NULL
,	NULL
A	NULL
.	NULL

Association	NULL
of	NULL
aberrant	NULL
transcortin	NULL
levels	NULL
with	NULL
HLAantlgensaMoftheBandClocl	NULL
high	NULL
transcortin	NULL
levels	NULL
are	NULL
frequently	NULL
found	NULL
in	NULL
patients	NULL
with	NULL
lymphatic	NULL
,	NULL
leukemia	NULL
,	NULL
hairy	NULL
cell	NULL
leukemia	NULL
,	NULL
or	NULL
non-Hodgkin	NULL
lymphoma	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

,	NULL
51	NULL
:	NULL
868-872	NULL
,	NULL
1980	NULL
.	NULL

Distethorst	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Benutto	NULL
,	NULL
B.	NULL
M.	NULL
Glucocorticoid	NULL
receptor	NULL
content	NULL
of	NULL
T	NULL
lymphocytes	NULL
:	NULL
evmnceforheterogeneny	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
126	NULL
:	NULL
1630-1634	NULL
,	NULL
1981	NULL
.	NULL

Duval	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Homo	NULL
,	NULL
F.	NULL
Prognostic	NULL
value	NULL
of	NULL
steroid	NULL
receptor	NULL
determination	NULL
in	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
4263-4267	NULL
,	NULL
1978	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
Mechanisms	NULL
of	NULL
corticosteroid	NULL
action	NULL
on	NULL
lymphocyte	NULL
subpopula-	NULL
tions	NULL
.	NULL

I	NULL
.	NULL

Redistribution	NULL
of	NULL
circulating	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
to	NULL
the	NULL
bone	NULL
marrow	NULL
.	NULL

Immunology	NULL
,	NULL
28	NULL
:	NULL
669-680	NULL
,	NULL
1975	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
Dale	NULL
,	NULL
D.	NULL
C.	NULL
The	NULL
effect	NULL
of	NULL
in	NULL
vivo	NULL
hydrocortisone	NULL
on	NULL
sul	NULL
ulations	NULL
of	NULL
human	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
53	NULL
:	NULL
240-246	NULL
,	NULL
1974	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Murakami	NULL
,	NULL
T.	NULL
,	NULL
Brandon	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Loriaux	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
and	NULL
Lipsett	NULL
,	NULL
M.	NULL
B.	NULL
Mechamsms	NULL
of	NULL
oomcosterood	NULL
action	NULL
on	NULL
lymphocyte	NULL
subpopulations	NULL
.	NULL

VI	NULL
.	NULL

Lack	NULL
of	NULL
correlation	NULL
between	NULL
glucocorticoid	NULL
and	NULL
the	NULL
differential	NULL
effects	NULL
of	NULL
glucocorticosteroids	NULL
on	NULL
T-cell	NULL
subpopulations	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
49	NULL
:	NULL
43-50	NULL
,	NULL
1980	NULL
.	NULL

Feldman	NULL
,	NULL
D.	NULL
Ontogeny	NULL
of	NULL
rat	NULL
hepatic	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Endocrinology	NULL
,	NULL
95	NULL
:	NULL
1219-1227	NULL
,	NULL
1974	NULL
.	NULL

Forker	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Bollinger	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Mortis	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Larson	NULL
,	NULL
W.	NULL
E.	NULL
Metabolism	NULL
of	NULL
cortisol-C	NULL
``	NULL
*	NULL
by	NULL
human	NULL
peripheral	NULL
leukocyte	NULL
cultures	NULL
from	NULL
leukemic	NULL
patients	NULL
.	NULL

Metab	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

,	NULL
12	NULL
:	NULL
751-759	NULL
,	NULL
1963	NULL
.	NULL

Galaini	NULL
,	NULL
S.	NULL
,	NULL
Minowada	NULL
,	NULL
J.	NULL
,	NULL
Siivernail	NULL
,	NULL
P.	NULL
,	NULL
Nussbaum	NULL
,	NULL
A.	NULL
,	NULL
Kaiser	NULL
,	NULL
N.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Shimaoka	NULL
,	NULL
K.	NULL
SDOCIfIC	NULL
glucooomcoud	NULL
binding	NULL
in	NULL
human	NULL
hemopouetic	NULL
cell	NULL
lines	NULL
and	NULL
tic	NULL
tissue	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
33	NULL
:	NULL
2653-2657	NULL
,	NULL
1973	NULL
.	NULL

Galli	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Galili	NULL
,	NULL
U.	NULL
Glucocorticoid	NULL
induced	NULL
lysis	NULL
of	NULL
various	NULL
subsets	NULL
of	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

in	NULL
:	NULL
Modern	NULL
Trends	NULL
in	NULL
Human	NULL
Leukemia	NULL
V	NULL
,	NULL
Hematology	NULL
and	NULL
Blood	NULL
Transfusion	NULL
,	NULL
Vol	NULL
.	NULL

28	NULL
,	NULL
in	NULL
press	NULL
,	NULL
1983	NULL
.	NULL

Galiili	NULL
,	NULL
U.	NULL
,	NULL
Prokocimer	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Izak	NULL
,	NULL
G.	NULL
The	NULL
in	NULL
vitro	NULL
sensitivity	NULL
of	NULL
leukemic	NULL
and	NULL
normal	NULL
leukocytes	NULL
to	NULL
hydrocortisone	NULL
induced	NULL
cytolysis	NULL
.	NULL

Blood	NULL
,	NULL
56	NULL
:	NULL
1077-1081	NULL
,	NULL
1980	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
Glucocorticoid-induced	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
growth	NULL
factor	NULL
production	NULL
.	NULL

I	NULL
.	NULL

The	NULL
effect	NULL
on	NULL
mitogen-induced	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
123	NULL
:	NULL
1624-1631	NULL
,	NULL
1979	NULL
.	NULL

Gregory	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Meyer	NULL
,	NULL
P.	NULL
Changes	NULL
in	NULL
cardiac	NULL
and	NULL
hepatic	NULL
glucocorticoid	NULL
receptors	NULL
after	NULL
adrenalectomy	NULL
.	NULL

Clin	NULL
.	NULL

Sci	NULL
.	NULL

Mol	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
517	NULL
:	NULL
487-	NULL
493	NULL
,	NULL
1976	NULL
.	NULL

Gupta	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Goldman	NULL
,	NULL
A.	NULL
H	NULL
;	NULL
histocompatibility	NULL
region	NULL
:	NULL
influence	NULL
on	NULL
the	NULL
mmgluoooomoondreoeptorandnsresponse	NULL
Science	NULL
(	NULL
Wash.	NULL
D.	NULL
C.	NULL
)	NULL
,	NULL
216	NULL
:	NULL
994-996	NULL
,	NULL
1982.	NULL
.	NULL

Ho	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Hunstein	NULL
,	NULL
W.	NULL
,	NULL
Ganeshaguru	NULL
,	NULL
K.	NULL
,	NULL
Hoffborand	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Brandeis	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
and	NULL
Denk	NULL
,	NULL
B	NULL
.	NULL

Therapeutic	NULL
and	NULL
prognostic	NULL
implications	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
terminal	NULL
deoxynucieotidy	NULL
!	NULL

transferase	NULL
in	NULL
acute	NULL
leukemia	NULL
,	NULL
Leukemia	NULL
Res	NULL
.	NULL

,	NULL
6	NULL
:	NULL
1-8	NULL
,	NULL
1982	NULL
.	NULL

Ho	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Hunstein	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Schmid	NULL
,	NULL
W.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
sensitivity	NULL
in	NULL
leukemias	NULL
.	NULL

Blut	NULL
,	NULL
42	NULL
:	NULL
183-190	NULL
,	NULL
1981	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Duval	NULL
,	NULL
D.	NULL
Human	NULL
thymus	NULL
cells	NULL
:	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
2	NULL
:	NULL
329-332	NULL
,	NULL
1979.	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Harousseau	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Marie	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Zittoun	NULL
,	NULL
R.	NULL
Hetero-	NULL
geneity	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
response	NULL
to	NULL
glucocorticoids	NULL
in	NULL
acute	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
40	NULL
:	NULL
2601-2608	NULL
,	NULL
1980.	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Hatzfeld	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Evrard	NULL
,	NULL
C.	NULL
Glucocorticoid	NULL
sensitive	NULL
and	NULL
resistant	NULL
cell	NULL
populations	NULL
in	NULL
the	NULL
mouse	NULL
thymus	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
13	NULL
:	NULL
135-143	NULL
,	NULL
1980.	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Meyer	NULL
,	NULL
P.	NULL
,	NULL
Belas	NULL
,	NULL
F.	NULL
,	NULL
Debre	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Binet	NULL
,	NULL
J.	NULL
L.	NULL
Chronic	NULL
lymphatic	NULL
leukemia	NULL
:	NULL
cellular	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
436	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

37	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

§1	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

55	NULL
.	NULL

57	NULL
.	NULL

59	NULL
.	NULL

61	NULL
.	NULL

62.	NULL
.	NULL

Ranelietti	NULL
,	NULL
38	NULL
:	NULL
491-499	NULL
,	NULL
1978.	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Thierry	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Serrou	NULL
,	NULL
B	NULL
.	NULL

Human	NULL
lym|	NULL
subpop-ulanonseffeclsofgluoooorticoidsmwtroJSteroadedtem	NULL
10	NULL
:	NULL
609-613	NULL
,	NULL
1979.	NULL
lacobelli	NULL
,	NULL
S.	NULL
,	NULL
Longo	NULL
,	NULL
P.	NULL
,	NULL
Mastrangelo	NULL
,	NULL
R.	NULL
,	NULL
Malandrino	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Ranaletti	NULL
,	NULL
F.O	NULL
.	NULL

kaoormdreceptowsandstemd	NULL
of	NULL
acute	NULL
leukemia	NULL
and	NULL
thymoma	NULL
.	NULL

in	NULL
:	NULL
S.	NULL
lacobelli	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

B	NULL
.	NULL

King	NULL
,	NULL
H.	NULL
R.	NULL
Lindner	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Upprnmm	NULL
(	NULL
eds	NULL
)	NULL
Hmna\esm\d0mp371	NULL
New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
.laoobeItS	NULL
Natolfi	NULL
,	NULL
V.	NULL
,	NULL
Longo	NULL
,	NULL
P.	NULL
,	NULL
Ranelletti	NULL
,	NULL
F.	NULL
O.	NULL
,	NULL
De	NULL
Rossi	NULL
,	NULL
G.	NULL
,	NULL
Pasqualeti	NULL
,	NULL
D.	NULL
,	NULL
Mandeli	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Mastrangelo	NULL
,	NULL
R.	NULL
Gluoooorﬂoonreeeptofdetenmnaﬂonm	NULL
leukenuapauemsusmgcytosolandwholecellassays	NULL
Cancer	NULL
Res	NULL
.	NULL

,	NULL
41	NULL
:	NULL
3979-3984	NULL
,	NULL
1981.	NULL
.	NULL

Jemkins	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Kemp	NULL
,	NULL
N.	NULL
H.	NULL
Metabolism	NULL
of	NULL
cortisol	NULL
by	NULL
human	NULL
feukemic	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
29	NULL
:	NULL
1217-1221	NULL
,	NULL
1969.	NULL
.	NULL

Kirkpatrick	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
Mitholland	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Rosen	NULL
,	NULL
F.	NULL
Stereospecific	NULL
glucocorticoid	NULL
binding	NULL
to	NULL
subcellular	NULL
fractions	NULL
of	NULL
the	NULL
sensitive	NULL
and	NULL
resistant	NULL
lymphosarcoma	NULL
P1798	NULL
.	NULL

Nat	NULL
.	NULL

New	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
232	NULL
:	NULL
216-218	NULL
,	NULL
1971	NULL
.	NULL

Kiein	NULL
,	NULL
A.	NULL
,	NULL
Bessler	NULL
,	NULL
H.	NULL
,	NULL
Hoogervorst	NULL
,	NULL
H.	NULL
,	NULL
Kaufmann	NULL
,	NULL
H.	NULL
,	NULL
Djaldetti	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Joshua	NULL
,	NULL
H.	NULL
A	NULL
difference	NULL
between	NULL
human	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
regarding	NULL
their	NULL
capacity	NULL
to	NULL
metabolize	NULL
cortisol	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
13	NULL
:	NULL
517-520	NULL
,	NULL
1980	NULL
.	NULL

Konior	NULL
Yarbro	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
subpopulations	NULL
of	NULL
childhood	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
37	NULL
:	NULL
2688-2695	NULL
,	NULL
1977.	NULL
.	NULL

Kontula	NULL
,	NULL
K.	NULL
,	NULL
AndersonJL	NULL
Paavonen	NULL
,	NULL
T.	NULL
,	NULL
MyltylaG	NULL
Teerenmovi	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Vuopio	NULL
,	NULL
P.	NULL
Glueocamotd	NULL
receptors	NULL
and	NULL
leukemic	NULL
cells	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
26	NULL
:	NULL
177-183	NULL
,	NULL
1980.	NULL
sensitivity	NULL
of	NULL
human	NULL
.	NULL

Kontula	NULL
,	NULL
K.	NULL
,	NULL
Paavonen	NULL
,	NULL
T.	NULL
,	NULL
Vuopio	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Andersson	NULL
,	NULL
L.	NULL
C.	NULL
Glucocorticoid	NULL
45.	NULL
receptors	NULL
in	NULL
hairy-cell	NULL
leukemia	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
30	NULL
:	NULL
423-426	NULL
,	NULL
1982	NULL
.	NULL

Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
lymphoid	NULL
tumors	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
41	NULL
:	NULL
4861-4862	NULL
,	NULL
1981	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Barr	NULL
,	NULL
R.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
purified	NULL
subpopulations	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
1178	NULL
:	NULL
1977-1981	NULL
,	NULL
1977	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Halterman	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
binding	NULL
proteins	NULL
in	NULL
human	NULL
acute	NULL
lymphoblastic	NULL
leukemic	NULL
blast	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
52	NULL
:	NULL
1715-1725	NULL
,	NULL
1973	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Konior	NULL
Yarbro	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Clinical	NULL
implications	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
human	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
4251-4256	NULL
,	NULL
1978	NULL
.	NULL

Marchetti	NULL
,	NULL
P.	NULL
,	NULL
Natoli	NULL
,	NULL
V.	NULL
,	NULL
Ranelietti	NULL
,	NULL
F.	NULL
O.	NULL
,	NULL
Mandelli	NULL
,	NULL
F.	NULL
,	NULL
De	NULL
Rossi	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
lacobelli	NULL
,	NULL
S.	NULL
Glucocorticoid	NULL
receptor	NULL
studies	NULL
in	NULL
leukemia	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
15	NULL
:	NULL
261-268	NULL
,	NULL
1981.	NULL
.	NULL

Mastrangelo	NULL
,	NULL
R.	NULL
,	NULL
Malandrino	NULL
,	NULL
R.	NULL
,	NULL
Riccardi	NULL
,	NULL
R.	NULL
,	NULL
Longo	NULL
,	NULL
P.	NULL
,	NULL
Ranelletti	NULL
,	NULL
F.	NULL
O.	NULL
,	NULL
and	NULL
lacoberlii	NULL
,	NULL
S.	NULL
Clinical	NULL
implications	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
studies	NULL
in	NULL
childhood	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
56	NULL
:	NULL
1036-1040	NULL
,	NULL
1980	NULL
.	NULL

Mauer	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Fisher	NULL
,	NULL
O	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
tive	NULL
of	NULL
acute	NULL
leukemia	NULL
cells	NULL
in	NULL
bone	NULL
marrow	NULL
and	NULL
blood	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
193	NULL
:	NULL
1085-1086	NULL
,	NULL
1962	NULL
.	NULL

McGuire	NULL
,	NULL
W.	NULL
L.	NULL
An	NULL
update	NULL
on	NULL
estrogen	NULL
and	NULL
progesterone	NULL
receptors	NULL
in	NULL
prognosis	NULL
for	NULL
primary	NULL
and	NULL
advanced	NULL
breast	NULL
cancer	NULL
.	NULL

in	NULL
:	NULL
Hormones	NULL
and	NULL
Cancer	NULL
,	NULL
p.	NULL
337	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1980	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Leung	NULL
,	NULL
K.	NULL
Glucocorticoid	NULL
receptor	NULL
and	NULL
mechanisms	NULL
of	NULL
action	NULL
.	NULL

In	NULL
:	NULL
J.	NULL
R.	NULL
Pasqualini	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

Receptors	NULL
and	NULL
Mechanism	NULL
of	NULL
Action	NULL
of	NULL
Steroid	NULL
Hormones	NULL
,	NULL
Part	NULL
2	NULL
,	NULL
p.	NULL
311	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Marcel	NULL
Dekker	NULL
,	NULL
1977.	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
D.	NULL
A.	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
tissue	NULL
.	NULL

/n	NULL
:	NULL
D.	NULL
F.	NULL
Steiner	NULL
and	NULL
N.	NULL
Freinkel	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Handbook	NULL
of	NULL
Physiology	NULL
,	NULL
Section	NULL
7	NULL
,	NULL
Vol	NULL
.	NULL

6	NULL
,	NULL
p.	NULL
231	NULL
.	NULL

Washington	NULL
,	NULL
D.	NULL
C.	NULL
;	NULL
American	NULL
Physiological	NULL
Society	NULL
,	NULL
1975	NULL
.	NULL

Nakao	NULL
,	NULL
Y.	NULL
,	NULL
Tsuboi	NULL
,	NULL
S.	NULL
,	NULL
Fujita	NULL
,	NULL
T.	NULL
,	NULL
Masakoa	NULL
,	NULL
T.	NULL
,	NULL
Morikawa	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Watanabe	NULL
,	NULL
S.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
terminal	NULL
deoxynucleotidy	NULL
!	NULL

transferase	NULL
activities	NULL
in	NULL
leukemic	NULL
cells	NULL
.	NULL

Cancer	NULL
(	NULL
Phila	NULL
.	NULL
)	NULL

,	NULL
47	NULL
:	NULL
1812-1817	NULL
,	NULL
1981.	NULL
.	NULL

Nanni	NULL
,	NULL
P.	NULL
,	NULL
Nicoletti	NULL
,	NULL
G.	NULL
,	NULL
Prodi	NULL
,	NULL
G.	NULL
,	NULL
Galli	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
De	NULL
Giovanni	NULL
,	NULL
C.	NULL
,	NULL
Grilli	NULL
,	NULL
S.	NULL
,	NULL
Lollini	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
Gobbi	NULL
,	NULL
M.	NULL
,	NULL
Cavo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Tura	NULL
,	NULL
S.	NULL
Glucocorticoid	NULL
receptor	NULL
and	NULL
in	NULL
vitro	NULL
sensitivity	NULL
to	NULL
steroid	NULL
hormones	NULL
in	NULL
human	NULL
lymphoproliferative	NULL
diseases	NULL
and	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Cancer	NULL
(	NULL
Phila	NULL
.	NULL
)	NULL

,	NULL
49	NULL
:	NULL
623-632	NULL
,	NULL
1982	NULL
.	NULL

Naray	NULL
,	NULL
A.	NULL
,	NULL
Revesz	NULL
,	NULL
T.	NULL
,	NULL
Walcz	NULL
,	NULL
E.	NULL
,	NULL
Schuler	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Horvath	NULL
,	NULL
I.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
acute	NULL
leukemia	NULL
of	NULL
childhood	NULL
.	NULL

Orv	NULL
.	NULL

Hetil	NULL
.	NULL

,	NULL
127	NULL
:	NULL
3175-3176	NULL
,	NULL
1980.	NULL
.	NULL

Neifeld	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
and	NULL
Torney	NULL
,	NULL
D.	NULL
C.	NULL
Steroid	NULL
hormone	NULL
receptors	NULL
in	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
252	NULL
:	NULL
2972-2977	NULL
,	NULL
1977	NULL
.	NULL

Nicholson	NULL
,	NULL
M.	NULL
L.	NULL
and	NULL
Young	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

An	NULL
effect	NULL
of	NULL
glucocorticoid	NULL
hormones	NULL
in	NULL
vitro	NULL
on	NULL
the	NULL
structural	NULL
integrity	NULL
of	NULL
nuclei	NULL
in	NULL
corticoid-sensitive	NULL
and	NULL
resistant	NULL
lines	NULL
of	NULL
tymphosarcoma	NULL
Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
3673-3680	NULL
,	NULL
1978	NULL
.	NULL

F.	NULL
O.	NULL
,	NULL
Carminagni	NULL
,	NULL
M.	NULL
,	NULL
lacobelli	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Tonali	NULL
,	NULL
P.	NULL
Glucoceorticoid-binding	NULL
components	NULL
in	NULL
human	NULL
thymus	NULL
hyperplasia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
516-520	NULL
,	NULL
1978	NULL
.	NULL

Ranelletti	NULL
,	NULL
F.	NULL
O.	NULL
,	NULL
lacobelli	NULL
,	NULL
S.	NULL
,	NULL
Carmignani	NULL
,	NULL
M.	NULL
,	NULL
Sica	NULL
,	NULL
G.	NULL
,	NULL
Natoli	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Tonali	NULL
,	NULL
P.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
in	NULL
vitro	NULL
sensitivity	NULL
in	NULL
human	NULL
thymoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
40	NULL
:	NULL
2020-2025	NULL
,	NULL
1980	NULL
.	NULL

Rosenau	NULL
,	NULL
W.	NULL
,	NULL
Baxter	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Rousseau	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
and	NULL
Tomkins	NULL
,	NULL
G.	NULL
M.	NULL
Mechanism	NULL
of	NULL
resistance	NULL
to	NULL
steroids	NULL
:	NULL
glucocorticoid	NULL
receptor	NULL
defect	NULL
in	NULL
lymphoma	NULL
cells	NULL
.	NULL

Nat	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

,	NULL
237	NULL
:	NULL
20-24	NULL
,	NULL
1972.	NULL
.	NULL

Schiechte	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Ginsberg	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
and	NULL
Sherman	NULL
,	NULL
B.	NULL
M.	NULL
Regulation	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
human	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
16	NULL
:	NULL
69-74	NULL
,	NULL
1982	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

69.	NULL
.	NULL

Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
.	NULL

Schrek	NULL
,	NULL
R.	NULL
Prednisolone	NULL
sensitive	NULL
and	NULL
cytology	NULL
of	NULL
viable	NULL
receptors	NULL
and	NULL
glutamine	NULL
synthetase	NULL
in	NULL
leukemic	NULL
Sézary	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
39	NULL
:	NULL
376-382	NULL
,	NULL
1979	NULL
.	NULL

Schrek	NULL
,	NULL
R.	NULL
Cytotoxicity	NULL
of	NULL
adrenal	NULL
cortex	NULL
hormones	NULL
on	NULL
normal	NULL
and	NULL
malignant	NULL
lymphocytes	NULL
of	NULL
man	NULL
and	NULL
rat	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
108	NULL
:	NULL
326-332	NULL
,	NULL
1961.	NULL
as	NULL
tests	NULL
for	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
.	NULL

Inst	NULL
.	NULL

,	NULL
33	NULL
:	NULL
837-847	NULL
,	NULL
1964.	NULL
.	NULL

Simonsson	NULL
,	NULL
B.	NULL
,	NULL
Terenius	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Nitsson	NULL
,	NULL
K.	NULL
Glucocorticoid	NULL
receptors	NULL
,	NULL
clinical	NULL
characteristics	NULL
,	NULL
and	NULL
implications	NULL
for	NULL
prognosis	NULL
in	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
(	NULL
Phila	NULL
.	NULL
)	NULL

,	NULL
49	NULL
:	NULL
2493-2496	NULL
,	NULL
1982.	NULL
.	NULL

Skoog	NULL
,	NULL
L.	NULL
,	NULL
Nordenskjoid	NULL
,	NULL
B.	NULL
,	NULL
Ost	NULL
,	NULL
A.	NULL
,	NULL
Andersson	NULL
,	NULL
B.	NULL
,	NULL
Hast	NULL
,	NULL
R.	NULL
,	NULL
Glannoulis	NULL
,	NULL
N.	NULL
,	NULL
Humla	NULL
,	NULL
S.	NULL
,	NULL
Hagerstrom	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Reizenstein	NULL
,	NULL
P.	NULL
Glucocorticoid	NULL
receptor	NULL
concentrations	NULL
and	NULL
terminal	NULL
transferase	NULL
activity	NULL
as	NULL
indicators	NULL
of	NULL
prognosis	NULL
in	NULL
acute	NULL
non-lymphocytic	NULL
leukemia	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

J.	NULL
,	NULL
262	NULL
:	NULL
1826-1829	NULL
,	NULL
1981	NULL
.	NULL

Stoman	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
P.	NULL
A.	NULL
Gilucocorticolds	NULL
and	NULL
myeloid	NULL
leukemia	NULL
.	NULL

/n	NULL
:	NULL
Glucocorticoid	NULL
Action	NULL
and	NULL
Leukemia	NULL
,	NULL
7th	NULL
Tenovus	NULL
Workshop	NULL
,	NULL
p.	NULL
161	NULL
.	NULL

Cardiff	NULL
,	NULL
FEBRUARY	NULL
1984	NULL
70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

GR	NULL
and	NULL
Sensitivity	NULL
in	NULL
Human	NULL
Lymphoid	NULL
Tissues	NULL
Wales	NULL
:	NULL
Alpha	NULL
Omega	NULL
Publishing	NULL
,	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Kennedy	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
U.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
glucocorticoid	NULL
sensitivity	NULL
of	NULL
mitogen	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
human	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
267	NULL
:	NULL
523-526	NULL
,	NULL
1977	NULL
.	NULL

Stevens	NULL
,	NULL
J.	NULL
,	NULL
Stevens	NULL
,	NULL
Y.	NULL
W.	NULL
,	NULL
and	NULL
Rosenthal	NULL
,	NULL
R.	NULL
L.	NULL
Characterization	NULL
of	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
glucocorticoid	NULL
binding	NULL
in	NULL
human	NULL
leukemic	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
39	NULL
:	NULL
4939-4948	NULL
,	NULL
1979	NULL
.	NULL

Stevens	NULL
,	NULL
J.	NULL
,	NULL
Stevens	NULL
,	NULL
Y.	NULL
W.	NULL
,	NULL
Stoan	NULL
,	NULL
E.	NULL
,	NULL
Rosenthal	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Rhodes	NULL
,	NULL
J	NULL
.	NULL

Nuclear	NULL
glucocorticoid	NULL
binding	NULL
in	NULL
chronic	NULL
lymphatic	NULL
leukemia	NULL
lymphocytes	NULL
.	NULL

Endocr	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
5	NULL
:	NULL
91-108	NULL
,	NULL
1978	NULL
.	NULL

Svec	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Rudis	NULL
,	NULL
M.	NULL
Glucocorticoids	NULL
regulate	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
the	NULL
AtT	NULL
20	NULL
cell	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
256	NULL
:	NULL
5984-5987	NULL
,	NULL
1981	NULL
.	NULL

Terenius	NULL
,	NULL
L.	NULL
,	NULL
Simonsson	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Nilson	NULL
,	NULL
K.	NULL
Glucocorticoid	NULL
receptors	NULL
,	NULL
DNA	NULL
synthesis	NULL
,	NULL
membrane	NULL
antigens	NULL
and	NULL
their	NULL
relation	NULL
to	NULL
disease	NULL
activity	NULL
in	NULL
chronic	NULL
lymphatic	NULL
leukemia	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
7	NULL
:	NULL
905-909	NULL
,	NULL
1976	NULL
.	NULL

437	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Glucocorticoid	NULL
Receptors	NULL
and	NULL
Steroid	NULL
Sensitivity	NULL
in	NULL
Normal	NULL
and	NULL
Neoplastic	NULL
Human	NULL
Lymphoid	NULL
Tissues	NULL
:	NULL
A	NULL
Review	NULL
Frangoise	NULL
Homo-Delarche	NULL
Cancer	NULL
Res	NULL
1984	NULL
;	NULL
44:431-437	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/44/2/431	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/44/2/431	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

